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UBQLN1: A MULTI-DOMAIN PROTEIN WITH MULTPLE FUNCTIONS 
Zimple Kurlawala 
July 25, 2017 
 There are 5 Ubiquilin proteins (UBQLN1-4, UBQLN-L), which are evolutionarily 
conserved and structurally similar. UBQLN proteins have 3 functional domains: N-
terminal ubiquitin-like domain (UBL), C-terminal ubiquitin-associated domain (UBA) 
and STI chaperone-like regions in the middle. Alterations in UBQLN1 gene have been 
detected in a variety of disorders including Alzheimer’s disease, Amyotropic Lateral 
Sclerosis and lung cancer. UBQLN1 has been largely studied in neurodegenerative 
disorders in the context of protein quality control. Several studies have hypothesized 
that the UBA domain of UBQLN1 binds to poly-ubiquitin chains of substrate and 
shuttles it to the proteasome via its UBL domain for degradation. UBQLN1 can both 
facilitate degradation (Ataxin3, EPS15) and stabilize (PSEN1/2, BCLb) substrates it 
binds. The signal that determines this fate is unknown and there is conflicting data to 
support the existing working model of UBQLN1.  
BCLb is a member of BCL2 family of proteins that maintain the balance 
between apoptosis and survival in cells. BCLb is anti-apoptotic and interacts with 
UBQLN1. Using BCLb as a model substrate, we characterized UBQLN1-substrate 
interaction. We identified the first two STI domains of UBQLN1 as critical for binding 
of the UBA domain to these proteins slows their degradation. Similarly, we showed 
that UBQLN1 interacts with IGF1R and ESYT2 through the STI domains and binding 
stabilizes these proteins through its UBA domain. Interactions that are not dependent 




appear to be stabilized by UBQLN1. We conclude that fate of substrates that UBQLN 
associates with, is interaction domain specific. We used data derived from UBQLN1-
BCLb interactions to model how UBQLN1 regulates IGF1R in lung adenocarcinoma 
cells. We have identified Ubiquilin1 as a novel interaction partner of IGF1R, IGF2R and 
Insulin Receptor. We demonstrate here that UBQLN1 regulates expression and activity 
of IGF receptors. Following loss of UBQLN1 in lung adenocarcinoma cells, there is 
accelerated loss of IGF1R post stimulation with ligand. Despite decreased levels of 
total receptors, the ratio of active:total receptors is higher in cells that lack UBQLN1. 
We tested for differences in synthesis, degradation, trafficking, autocrine ligand 
production, survival, migration potential and response to chemotherapy in lung 
adenocarcinoma cells that have loss of UBQLN1. UBQLN1 also regulates ligand 
stimulated IGF2R, Insulin Receptor (INSR), Epidermal Growth Factor Receptor 
(EGFR). UBQLN1 deficient cells demonstrate increased survival when serum starved 
and stimulation of IGF pathway in these cells increased their migratory potential by 3-
fold. In conclusion, UBQLN1 is essential for normal regulation of these receptor 
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UBQLN Proteins  
Ubiquilin proteins are implicated 
in a variety of diseases like Alzheimer’s 
disease, Amyotropic Lateral Sclerosis, 
Fronto-Temporal dementia, triple repeat 
pathologies and even in lung, bone and 
urothelial cancers. How loss of function 
of a protein can lead to diverse outcomes 
in different cell types is 
intriguing. For this 
dissertation, we were 
interested in 
understanding the 
mechanism of action of 
UBQLN1 and how it 
relates to differential 
regulation of its 
substrates.  
The Ubiquilin 
family of proteins 
(UBQLN1-4, UBQLNL) 
are evolutionarily 
Figure 1: Schematic of structural 
domains of UBQLN1. UBL domain: 
UBiquitin-Like domain. STI-1,2,3,4 
domains: STress-Inducible proteins. 
These domains mediate protein-protein 
interactions. UBA domain: UBiquitin-














UBQLN1 9q21.32 589 100 All 






UBQLN3 11p15.4 655 48 Testis 










Table 1: UBQLN family members, their chromosomal 
location and tissue distribution. Percent of sequence 




Table 2: Interacting partners of UBQLN 
  Interacting Partner Mapped Domains 
Cell Surface Receptors 
1 IAP(A. L. Wu, Wang, Zheleznyak, & Brown, 1999) UBL  
2 Presinilin1 and 2(Mah, Perry, Smith, & Monteiro, 2000) 
UBA and COOH tail 
mediated.  
3 GABAA (Bedford et al., 2001) 
UBA  
(GABAA: between Tm 
domains 3 and 4 of the 
alpha1 subunit) 
4 IGF1R (Kurlawala, Shah, Shah, & Beverly, 2017) INSR STI-1 and STI-2 
5 GPCR’s (N'Diaye et al., 2008) Not mapped 
6 nAChR(Ficklin, Zhao, & Feng, 2005) Not mapped 
7 ESYT2 (Kurlawala et al., 2017) STI-1 and STI-2 
Proteasomal Machinery 
8 S5a (Rpn10a), (Ko, Uehara, Tsuruma, & Nomura, 2004) Rpn3, Rpn10e UBL 
9 PSMC2 (Muller-Vahl, Kolbe, & Dengler, 1997) Not mapped 
Transmembrane Proteins 
10 K7(Feng et al., 2004) UBA 
11 Omp25 (Itakura et al., 2016) Not mapped 
12 12 Mtb proteins (Sakowski et al., 2015) Not mapped 
13 
BCLb (Beverly, Lockwood, Shah, Erdjument-
Bromage, & Varmus, 2012; Kurlawala et al., 
2017) 
STI-1 and STI-2 
Others 
14 
Ubiquitin(Feng et al., 2004; Ko, Uehara, & 
Nomura, 2002; Kurlawala et al., 2017; Massey 
et al., 2004; D. Zhang, Raasi, & Fushman, 
2008) 
 
15 HERC3 (Hochrainer, Kroismayr, Baranyi, Binder, & Lipp, 2008) Not mapped 
16 EPS15, EPS15R, Hrs, Hbp (Regan-Klapisz et al., 2005) UBL 
17 
UBQLN1 homodimer (Feng et al., 2004; 
Kurlawala et al., 2017) 
UBQLN2 heterodimer (Feng et al., 2004; 
Hjerpe et al., 2016) 
STI-4 (homodimer) 
18 mTOR (S. Wu et al., 2002) STI-1 and STI-2 (226-323) 
19 E6AP, several proteasomal proteins (Kleijnen et al., 2000) Not mapped 




conserved and structurally similar to each other. These proteins are highly similar in 
sequence identity, encoded by genes on different chromosomes and have varied 
tissue distribution (Table 1) (Beverly et al., 2012). UBQLN1 is approximately 63 kDa 
protein and all its family members have 3 main domains: ubiquitin-like domain (UBL) 
at the N-terminus, ubiquitin-associated domain (UBA) at the C-terminus and STI 
chaperone-like regions in the middle (Fig. 1). UBQLN1 maintains all the functionally 
important motifs present in this group (Massey et al., 2004) is ubiquitously expressed 
in all tissues. The UBL domain of UBQLN is structurally similar to ubiquitin and 
interacts proteasomal cap (S5a) (Buchberger, 2002) while the UBA domain associates 
with ubiquitin (Wilkinson et al., 2001; D. Zhang et al., 2008).  
The central region consisting of STI domains are called so because of their 
similarity to STI-1 proteins (STress Inducible proteins or Hsp70-Hsp90 organizing 
protein, HOP). This region acts as a co-chaperone and mediates hydrophobic 
interactions with other proteins (Mueller, Kamionka, & Feigon, 2004; L. Zhao & 
Ackerman, 2006). Current working model of UBQLN1 is hypothesized as: the UBL 
domain of Ubiquilin1 binds to the proteasome while the UBA domain binds to ubiquitin 
on the substrate protein and aids in the substrate’s degradation (Buchberger, 2002).  
 There are 2 types of UBL-UBA proteins: type-1 like SUMO and NEDD1 which 
covalently attach to ubiquitin and type-2 proteins like UBQLN, Rad23, Parkin, Bat-3, 
Elongin-b, Bag-1 and so on that associate with ubiquitin through its UBA domain in a 
non-covalent manner. As a type-2 UBL-UBA protein, UBQLN proteins are mostly 
studied in the context of ubiquitination, protein degradation and protein quality control 
and are largely implicated in development of neurodegenerative disorders. Table 1 
shows a list of published substrates of UBQLN1. Ubiquilin1 interacts with a variety of 
proteins – involved in the proteasomal machinery (PSMD4, BAG6, S5a, Rpn3, 
Rpn10e) (Kurlawala et al., 2017), cell surface receptors (IAP, GABA-A (Saliba, 
Pangalos, & Moss, 2008) , GPCR’s (N'Diaye et al., 2008), Presinilins 1/2 (Mah et al., 




regulators (IκBα) (Feng et al., 2004) and intracellular transmembrane proteins 
ESYT2 (Kurlawala et al., 2017), CD47 (A. L. Wu et al., 1999), BCLb (Beverly et al., 
2012), OMP25 (Itakura et al., 2016), and others like ubiquitin, E3 ligases and so on. 
Additionally, Ubiquilin1 function is implicated in diverse cellular processes like ERAD 
(endoplasmic reticulum associated degradation) (Lim et al., 2009; Shah et al., 2015),  
autophagy (Lee, Arnott, & Brown, 2013; Elsa-Noah N'Diaye et al., 2009; Sun et al., 
2015), apoptosis (Lu et al., 2009) and epithelial to mesenchymal transition (EMT) 
(Shah et al., 2015; Yadav et al., 2017). 
 
UBQLN1 and Ubiquitin 
 The most well understood interacting partner of UBQLN proteins is ubiquitin. 
Ubiquitin is a 7 kD molecule that covalently binds to lysine residues on proteins. One 
ubiquitin molecule has 7 lysine residues (K6, K11, K27, K29, K33, K48, K63).  Ubiquitin 
is capable of mono-ubiquitinating proteins and forming ubiquitin chains through one or 
more of its 7 lysines. The process of ubiquitination involves 3 ubiquitin ligases – 
E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3, 
which recruits an E2 ubiquitin-conjugating enzyme that has been loaded 
with ubiquitin, recognizes a protein substrate, and assists in or directly 
catalyzes the transfer of ubiquitin from the E2 ligase to the protein substrate. 	
 Ubiquilin associates non-preferentially with mono- and poly-ubiquitin linkages 
through its UBA domain (Feng et al., 2004; Ko et al., 2002; Kurlawala et al., 2017; 
Massey et al., 2004; D. Zhang et al., 2008). The most widely accepted working model 
of UBQLN1 suggests that UBQLN1 associates with ubiquitin on its substrates through 
its UBA domain, while the UBL domain (known interactor of the proteasome) directs it 
for degradation. However, UBA domain of UBQLN1 can act as a receptor for ubiquitin 
on substrates, and shield them from degradation thus stabilizing the substrate. It is 




of Ubiquilin1 with its substrate. Interestingly, Ubiquilin1 is also reported to interact with 
three E3 ligases -- E6AP and bTRCP (Kleijnen et al., 2000), and HERC3 (Hochrainer et 
al., 2008). Upon interaction with E6AP and bTRCP, UBQLN1 and UBQLN2 prevent 
degradation of their substrates - tumor suppressor p53 and TNFa-induced rapid 
degradation of inflammatory mediator IkBa, respectively. Overexpression of UBQLN 
proteins did not block the proteasome as the control protein Ornithine Decarboxylase, 
a known substrate of the proteasome continued to be degraded at its usual rate. 
Therefore, it is likely that UBQLN1 interaction with E3 ligases prevents a step that is 
common to both pathways in the presence of overexpressed UBQLN’s. In contrast, 
Hochrainer et al showed that UBQLN1 interacts with HERC3, another E3 ligase and 
stabilizes HERC3’s interaction with proteasome and NFkB. UBQLN1 strengthens 
binding of HERC3 to RelA, which delivers RelA to proteasome and thus has a 
degradation enhancing role for NFkB (Hochrainer et al., 2008; Hochrainer et al., 2015). 
Therefore, it strengthens the hypothesis that UBQLN1 does have substrate specific 
functions.  
 
UBQLN and Cell Surface Receptors 
The largest group of known substrates of UBQLN proteins are cell surface 
receptors, namely CD47, Presinilins, GABAA, IGF1R, GPCR’s. Here, we’ll review the 
ways Ubiquilin regulates these proteins.  
Ubiquilins were originally discovered as Proteins Linking IAP with Cytoskeleton 
(PLICs) by Wu Ai-Ling in 1999 as proteins that interact with CD47 (integrin associated 
protein, IAP) that anchor vimentin filaments to the plasma membrane. UBQLN1 and 
UBQLN2 were distribution was contained in the cytoplasm and membranes of 
adherent, suspension as well as cytochalasin D (inhibitor of actin polymerization) 
treated cells (A. L. Wu et al., 1999) and their overexpression increased cell spreading 




Soon after, Presenilin1 and Presinilin2 were identified as new interacting 
partners of UBQLN1 (Mah et al., 2000) and this discovery was of particular interest in 
the 1990’s since mutations in familial cases of Alzheimer’s had recently been identified 
in Presinilin and APP genes. Overexpression of UBQLN1 in HeLa cells led to 
increased expression (number of receptors) of Presenilins without increase in 
synthesis or altering protein degradation. This indicates that UBQLN1 may enhance 
post translational modifications of Presenilins in a way that presence of UBQLN1 
prevents Presenilins’ untimely loss (Mah et al., 2000; Massey et al., 2004). 
Additionally, UBQLN1 decreased ubiquitination of Presinilins and as a result 
decreased its fragmentation in the gamma secretase complex into N-terminal and C-
terminal fragments (NTF and CTF). The NTF and CTF fragments of Presenilins form 
the catalytic core of the gamma secretase complex (Massey, Mah, & Monteiro, 2005). 
Both, overexpression of UBQLN1 and blocking of the proteasome with multiple 
inhibitors inhibited fragmentation of Presinilins. Therefore, UBQLN1 plays a role via 
the proteasome, either directly or indirectly, in regulating components of the gamma 
secretase complex. UBQLN1 also effected other components of the gamma secretase 
complex namely Pen2, Aph-1 and Nicastrin. Overexpression of UBQLN1, increased 
levels of Pen2 simultaneously as Presenilin fragmentation increased and Aph-1 and 
mature Nicastrin levels were decreased.  
 UBQLN1 interacts with another cell surface receptor in neurons, GABAA 
receptors (Bedford et al., 2001). UBQLN1 overexpression enhanced cell surface levels 
of GABAA receptors demonstrated by ELISA (Bedford et al., 2001) and biotinylation 
assays (Saliba et al., 2008). Overexpression of UBQLN1 increased half-life of GABAA 
receptors and prevented its loss upon proteasomal inhibition.  Disruption of interaction 
between UBQLN1 with GABAA receptors produced a rapid decrease in its cell surface 
receptor expression within minutes of loss of interaction, suggesting that UBQLN1 may 
play a role in maintaining anchorage of GABAA in the plasma membrane. Additionally, 




vesicles, intracellular membranes and inhibitory synapses suggesting that UBQLN1 
may also play a role in stabilizing both recycled and de novo synthesized GABAA 
receptors. Transmembrane proteins like GABAA receptors usually require assembly in 
the Endoplasmic Reticulum once they are translated. These receptors are conjugated 
with high mannose N-linked glycans in the ER, that are sensitive to cleavage by the 
enzyme, Endoglycosidase H (Endo H). Endo H enzyme is commonly used to study 
post translational modifications by specifically removing high mannose N-linked 
carbohydrates from substrates. Once proteins the ER for Golgi for further processing, 
they are conjugated with mature N-linked glycans which are insensitive to cleavage by 
Endo H. Overexpression of UBQLN1 increased the amount of Endo H sensitive GABA 
in the ER by ~30% thus confirming a role for UBQLN1 in stabilizing newly translated 
transmembrane proteins in the ER (Saliba et al., 2008). Additionally, UBQLN1 also 
increased ubiquitinated GABA-R, enhanced cell surface accumulation of recombinant 
GABA beta3 subunits in neurons and increased insertion of GABAA into neuronal 
plasma membranes. 	
UBQLN1’s UBA domain binds to K7, a small membrane protein in Kaposi 
Sarcoma Associated Herpes Virus infected cells (Feng et al., 2004) and regulates in 
similar fashion as it regulates GABAA receptors. As seen with Presenilins and GABAA 
receptors, overexpression of UBQLN1 increased overall expression of K7. K7 has a 
half-life of 30 minutes and undergoes proteasomal degradation. Overexpressing 
UBQLN1 increased half-life of K7 by 12-fold mediated exclusively by its UBA domain 
as overexpressing UBA domain by itself and AP1, a UBA domain harboring protein, 
also prevent loss of K7 through proteasomal degradation implying that UBQLN1 binds 
to K7 through its UBA domain and may be preventing its proteasomal degradation thus 
stabilizing it (Feng et al., 2004). UBA domain overexpression also prevented loss of 
p53 and IkBa, substrates that are known to be stabilized by UBQLN1 overexpression. 




UBQLN1, and accelerated degradation of p53 and IkBa, likely due to occupancy of 
UBA domain by K7.  
UBQLN1 interacts with the a3, a4 and b4 subunits of nicotinic acetylcholine 
receptors (nAchR’s) in SCG neurons. Overexpression of UBQLN1 prevented nicotine-
induced upregulation of cell surface nAchR’s assessed by biotinylation assays and 
immunofluorescence staining (Ficklin et al., 2005).  UBQLN1 was identified to bind to 
12 cell surface proteins (Mtb’s) of Mycobacterium Tuberculosis in macrophages. 
UBQLN1 enhances ubiquitination of these Mtb’s and promoted IFNg driven autophagy 
to restrict growth of these bacteria (Sakowski et al., 2015).  
Overall, UBQLN1 interacts with several cell surface receptors. Overexpression 
of UBQLN1 stabilizes expression of Presenlins, GABAA receptors, K7 protein. 
Although its exact function is not known, it is likely that UBQLN1 functions to anchor 
receptor complexes in the plasma membrane and prevents their untimely activation 
and degradation.  
 
Other interacting partners of UBQLN1 
 Wu et al 2002, identified and studied interaction of UBQLN1 with the protein 
kinase, mTOR (S. Wu et al., 2002). Region 226-323 i.e. parts of STI-1 and STI-2 
domains of UBQLN1 were mapped to interact with catalytically inactive region of 
mTOR. By sucrose density gradient fractionations, mTOR was detected with 10% of 
total Ubiquilin1 in low density membranes. The biological relevance of interaction 
between these proteins is known as expression of UBQLN1 did not alter 
phosphorylation status of this kinase or its targets like p70 (S6 kinase). Hypoxia 
induced expression of UBQLN1 and an ER enzyme Protein Disulfide Isomerase (PDI) 
in neuronal cells. Their upregulation and interaction with each other protected neuronal 
cells from hypoxia induced ER stress and DNA fragmentation (apoptosis) (Ko et al., 




motifs (UIMs) which are like UBA domains and therefore can interact with ubiquitin or 
or ubiquitin like domains (UBLs). These endocytic proteins interact with UBQLN1’s 
UBL domain. Overexpression of UBQLN1 causes sequestration of these endocytic 
proteins into ubiquitin rich cytosolic aggregates (Regan-Klapisz et al., 2005). UBQLN2 
was identified to heteromerize with other UBQLN1 (UBQLN1, UBQLN2 and UBQLN4) 
and its interaction with HSP70 mediates unfolding of substrates and lead to their 
proteasomal degradation independent of autophagy.  Disease mutations of UBQLN2 
inhibit this interaction and lead to aggregations and degeneration in neurons (Hjerpe 
et al., 2016). UBQLN1 can bind transmembrane proteins in the cytosol and prevent 
them from aggregating. UBQLN was proposed to exist in a closed conformation 
(interaction of UBL domain of one UBQLN molecule with UBA domain of same or other 
UBQLN molecules) and supposed to “open” when there is a substrate (Itakura et al., 
2016). Dsk2p, the yeast homolog of UBQLN1, forms a trimeric complex with Rad23p 
and Cdc48 and enables degradation of misfolded proteins via the proteasomal system 
(Medicherla, Kostova, Schaefer, & Wolf, 2004). In human cells, the UBL domain of 
UBQLN1 has been shown to regulate degradation of misfolded proteins like Ataxin3, 
HSJ1a and EPS15 (Heir et al., 2006). UBQLN1 expression aids in poly-ubiquitination 
of viral polymerase NS5B, decreasing its half-life in HCV infected hepatocytes (Gao et 
al., 2003). Identifying functions of Ubiquilin proteins is an ongoing area of research. 
UBQLN1 is a stress-response protein; its expression protects astrocytes from hypoxia 
(Ko et al., 2002) and HeLa cells from starvation-induced death (E. N. N'Diaye et al., 
2009). In 2010, Rothenberg et al showed that UBQLN1 interacts with autophagy 
marker LC3 in a complex with other proteins and reduction in UBQLN1 expression 
decreases autophagy levels in HeLa cells, brain and liver tissue of mice (Rothenberg 







UBQLN in Neurodegenerative Disorders 
UBQLN1 and UBQLN2 are members of UBQLN family that are primarily 
implicated in neurodegenerative disorders. UBQLN2 has an extra collagen like domain 
where majority of ALS mutations are found. UBQLN2 mutations cause defects in 
autophagy and drive accumulation of TDP43, etc. Presenilin proteins (PS1 and 2) are 
well-established Alzheimer’s disease-associated proteins (Tanzi & Bertram, 2005). 
UBQLN1 binds to and stabilizes Presinilin1 and 2 and co-localize in a vesicular-like or 
ER-like pattern (Gao et al., 2003; Massey et al., 2004). A meta-analysis in 2014 
confirmed that a single intronic C/T polymorphism in UBQLN1 (UBQ-8i) significantly 
increased risk of Alzheimer’s disease (Bertram et al., 2005; T. Zhang & Jia, 2014). In 
the presence of this polymorphism, the STI domains of UBQLN1 are unable to bind to 
Presinilin proteins as a result of which a gamma secretase complex is formed 
generating Aβ40 and Aβ42 amyloid aggregations (Ford & Monteiro, 2007; Mah et al., 
2000; C. Zhang & Saunders, 2009). Ford et al (2006) hypothesize that UBQ-8i 
polymorphism favors formation of UBQLN dimers and loses its ability to bind to PS 
proteins. Neurofibrillary tangles and Lewy bodies in brains of Alzheimer’s disease and 
Parkinson’s patients robustly stained for anti-UBQLN antibodies provide more 
evidence to the role of UBQLN in these diseases (Mah et al., 2000). 
UBQLN1 is also implicated in pathogenesis of triplet repeat neurodegenerative 
diseases especially ones characterized by expanded polyglutamine (PolyQ) tracts. Of 
the nine different types of PolyQ diseases, UBQLN1 plays a role in Huntington’s 
disease (HD) and spinocerebellar ataxia type1 (Riley & Orr, 2006). The expansion of 
glutamine tracts leads to aggregation of the affected protein as it is unable to get 
degraded effectively in absence of UBQLN1. In an animal model of Huntington’s 
disease, UBQLN4 expression was identified to be protective as it decreased polyQ-
induced protein aggregation though its interaction with Ataxin1 and UBQLN1 (H. Wang 
& Monteiro, 2007).. UBQLN2 mutations have been identified in X-linked Amyotropic 




inclusions are detected in spinal cord of ALS patients and in hippocampus of ALS 
patients with dementia proposing a role of mutant UBQLN2 aggregation in 
neurodegeneration (Deng et al., 2011). 
 
Ubiquilins in Cancer 
 
 UBQLN1 is linked to development and progression of cancers such as 
neuroblastoma, lung adenocarcinomas, urothelial carcinoma and osteosarcomas. 
UBQLN1 aka DA41 in 1997, was identified as an interacting partner of a tumor 
suppressor protein DAN, frequently deleted in neuroblastoma (Ozaki et al., 1997). 
DA41 overexpression in Rous sarcoma virus transformed rat fibroblasts (Ras-3Y1), 
caused a decrease in cell proliferation and colony formation of these transformed cells 
(Ozaki, Nakamura, Hanaoka, Nakagawara, & Sakiyama, 2000).  Similarly, exogenous 
DAN expression in Ras-3Y1 cells depleted of endogenous DAN, caused arrest in their 
DNA synthesis. DA41 or UBQLN1 was believed to suppress overall growth through 
interaction with a cell cycle regulator, CDK2 and DAN. Additionally, DA41’s STI 
domains (155-232) were mapped as region of interaction with another protein called 
S(1-5), which bears several EGF like repeats, also capable of controlling cell cycle 
(Ozaki et al., 1997).  Funakoshi and colleagues found XDRP1 in 1999, a Xenopus 
orthologue that is 60% similar to Ubiquilin1, which interacted with another cell cycle 
regulator, Cyclin A, preventing its degradation and arresting cell division in frog 
embryo. Basic helix-loop-helix (bHLH) proteins are a large family of transcription 
regulators that function in critical developmental processes of the nervous system. 
HASH-1 is a bHLH protein, overexpressed in pediatric malignancies like 
neuroblastoma. HASH-1 and HES-1, another bHLH protein, interact with UBQLN1 in 
neuroblastoma cells. Overexpression of UBQLN1 leads to their accumulation and co-
expression of HASH-1 and UBQLN1 causes UBQLN1 to translocate to the nucleus 
(Persson, Stockhausen, Pahlman, & Axelson, 2004). This was the first evidence that 




human fetal midbrain stem cell line identified downregulation in expression of UBQLN1 
as the stem cells underwent differentiation from Day 0 to Day 7 (Hoffrogge et al., 2006). 
Therefore, aberrations in UBQLN1 function can potentially lead to developmental 
irregularities and even loss of cell cycle control as in cancer. UBQLN1 mRNA and 
protein levels were increased in the nine tumor and adjacent normal tissues examined 
and UBQLN1 overexpression was identified as a target candidate for humoral immune 
response in sera of 2 large lung cancer patient samples (150 patient vs. 100 control 
and 62 patient vs. 60 control) (Chen et al., 2007). Shimada et al report that urothelial 
cancer cells produce high levels of reactive oxygen species and consequently have 
increased levels of UBQLN2 to protect from ROS induced damage. Therefore, 
immunocytochemistry staining of UBQLN2 can be used to distinguish between 
neoplastic and non-neoplastic cells in urine. Additionally, nuclear staining of urothelial 
cancer cells corresponded with a higher grade of cancer (Shimada et al., 2016). A 
cisplatin-sensitive human ovarian carcinoma cell line was treated with AuL12 and 
Au2Phen, cytotoxic gold compounds, known to be potent antiproliferative agents to discover 
that these compunds resulted in increased expression of UBQLN1 which inhibited 
degradation of p53 and thus prevented tumor proliferation (Guidi et al., 2012). UBQLN1 
was reported to be lost in approximately fifty percent of non-small cell lung 
adenocarcinomas (Shah et al., 2015). siRNA mediated loss of UBQLN1 and mir155 
mediated downregulation of UBQLN1 in lung cancer cells has been shown to promote 
an EMT-like phenotype. It has been shown that downregulation of UBQLN1 leads to a 
significant increase in mesenchymal markers, including Vimentin, Snail and ZEB1 and 
therefore, UBQLN1 has been suggested to play a role in suppression of metastasis in 
lung cancer (Yadav et al., 2017). However, overexpression of UBQLN1 in lung cancer 
cells (Chen et al., 2007) and UBQLN2 in osteosarcomas (Tsukamoto et al., 2015) have 
also been reported. At the protein level, UBQLN1 stabilizes tumor suppressor p53 
(Feng et al., 2004; Kleijnen et al., 2000) as well as anti-apoptotic protein BCLb (Beverly 




as a regulator of anti-apoptotic protein Bcl2L10/Bclb (Beverly et al., 2012). We have 
reported that UBQLN1 is lost in about 50% of lung adenocarcinomas and tissue 
samples have varying UBQLN1 mRNA levels. We have also shown that loss of 
UBQLN1 or UBQLN2 promotes epithelial to mesenchymal transition (EMT) in lung 
adenocarcinoma cell lines (Shah et al., 2015). Thus, it is fallible to conclude a definitive 
role of UBQLN proteins in cancer development until large sample sizes and deeper 
stratification of patients and subtypes of cancers have been investigated. Equally 
important is understanding how Ubiquilin1 differentially regulates multiple substrates 
thus providing a clearer insight into Ubiquilin related diverse findings in cancers. 
 Considering the range of substrates and cellular processes Ubiquilin1 is 
involved in, we hypothesize that Ubiquilin1 is a versatile, multi-purpose adaptor, 
housing domains for binding to other proteins leading to functional specificity of 














Fate of substrates that UBQLN1 associates with is interaction-domain specific. 
Overall Goal 
The overall goal of this dissertation work is to understand the mechanism of action of 
UBQLN1 in regulating BCLb and IGF1R.  
Specific Aims 
1. To investigate biochemical functions of UBQLN1  
i. Identify domains of UBQLN1 responsible for interaction with multiple substrates 
ii. Determine role of UBQLN1 on substrate stability 
2. To investigate role of UBQLN1 in regulation of receptor tyrosine kinases  
i. Determine role of UBQLN1 in trafficking and turnover of IGF1R 
ii. Determine biological consequences of UBQLN1 loss and dysregulation of IGF 
pathway in lung adenocarcinoma cells.  
iii. Determine role of UBQLN1 in regulation of INSR and EGFR 
UBQLN1 either facilitates degradation or stabilizes substrates it binds to. The signal 
that determines this fate is unknown. Data supporting the existing working model of 
UBQLN1 is variable. Using BCLb as a model substrate, we examined characteristics 
of UBQLN1-BCLb and UBQLN1-IGF1R interaction. We hypothesize that UBQLN1 
expression normally acts to prevent untimely loss of IGF1R and terminate 
phosphorylation signal of activated IGF1R in lung adenocarcinoma cells. By doing so, 
it aids in controlled regulation of downstream signaling pathways. We studied in detail 






MATERIALS AND METHODS 
Cell Culture  
293T cells were cultured in DMEM supplemented with 10% FBS. DNA transfections were 
done using PEI (2.5:1). All cell extracts were prepared following scrape harvesting of 293T 
cells using CHAPS lysis buffer (1% CHAPS detergent, 150 mM NaCl, 50 mM Tris pH 7, 5 
mM EDTA). Subcellular fractionation experiments were performed using the ProteoExtract 
Subcellular Proteome Extraction kit (Calbiochem/Merck), as per the manufacturer’s 
protocol. For immunoprecipitations, 400 ug of protein was incubated in 400 uL of total 
CHAPS buffer and incubated with indicated affinity matrix for 1 h at 4 °C. Following 
incubation, the matrix was washed three times in CHAPS buffer and then SDS loading 
buffer was added directly to washed matrix, boiled, and loaded directly into the wells of a 
PAGE gel. Drug treatments were performed as described in the text using 20uM 
Cycloheximide, 25 uM proteasome inhibitor MG132, 360nM Epoximide, 1uM Bortezomib. 
Human non-small cell lung adenocarcinoma cell lines A549 were purchased from 
American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in RPMI 
medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 
1% antibiotic/antimycotic (Sigma, St Louis, MO, USA). The 3 cell lines were routinely 
subcultured every 3–4 days. All siRNA transfections were performed using Dharmafect1 
#T-2001-03 (Thermo Fisher Scientific Inc, Pittsburgh, PA, USA) as per manufacturer’s 




 which IGF1 50ng/ml was added to stimulate the cells. For protein stability studies, 
Cycloheximide (20uM), and for testing degradation pathways, Bortezomib (1uM) and 
Monensin (10uM) were added an hour prior to stimulating with IGF1. At the end of 
stimulation for various time points, cells were harvested in CHAPS lysis buffer (1% CHAPS 
detergent, 150mM NaCl, 50mM Tris pH 7, 5mM EDTA) supplemented with protease and 
phosphatase inhibitors. Protein was quantified by using Pierce's BCA Protein Assay 
Reagent Kit (# 23227) from Pierce Biotechnology, Rockford, IL, USA as per 
manufacturer’s protocol.    
Plasmids 
All experiments using expression of BCLb proteins were performed with vectors 
engineered for this study. The following accession numbers were used to design oligos 
for PCR based cloning from cDNA libraries generated from a “universal human RNA” 
library (Stratagene/Agilent Technologies): BCLb #NM_020396. FLAG-tagged BCL2 
constructs were generated by performing PCR of the MIG- BCL constructs using an oligo 
that fused the FLAG coding sequences to the amino terminus of each BCL2-protein. This 
product was then subcloned back into the MIGRX vector. The following plasmids were 
obtained from Addgene; FLAG-Ubqln (Addgene plasmid 8663, deposited by Peter 
Howley), FLAG-Ubqln-112X (Addgene plasmid 8664, deposited by Peter Howley), pRK5- 
HA-Ubiquitin-WT (Addgene plasmid 17608, deposited by Ted Dawson), pRK5-HA-
Ubiquitin- K0 (Addgene plasmid 17603, deposited by Ted Dawson), pRK5-HA-Ubiquitin-
K48 (Addgene plasmid 17605, deposited by Ted Dawson), GFP- BCL2 (Addgene plasmid 
17999, deposited by Clark Distelhorst). The GFP-tagged BCLb construct was purchased 
from OriGene catalogue #RG211604. Lysine-less BCLb construct was engineered using 
the MIG- or MIT-BCLb constructs described above to do site directed mutagenesis with 




manufacturer’s protocol. MYC-UBQLN1 construct was a gift from Annakaisa Haapasalo, 
Finland. Domain deletion constructs of UBQLN1 were created using the Q5 Site-Directed 
Mutagenesis Kit (New England Biolabs). Antibodies-BCLb #ab45412 and GFP #ab6673 
(Abcam); VDAC #4866 (Cell Signaling); IGF1R #3018 (Cell Signaling), ESYT2 
#HPA002132 (SIGMA), S5a/PSMD4 #12441 (Cell Signaling), BAG6 #A302-039A-T 
(Bethyl), MYC #F2512 (Santa cruz), Tubulin #B512, FLAG M2 conjugated agarose beads, 
FLAG poly-clonal #F7425 (Sigma); UBQLN poly-clonal was made by inoculating rabbits 
with a peptide specific to UBQLN1 (Yenzym Antibodies LLC); HA affinity matrix and HA 
#3F10 (Roche).  
Immunoprecipitation and Western Blot Analysis 
HEK 293T cells were cultured in DMEM supplemented with 10% FBS. DNA transfections 
were done using PEI (PEI 2.5:1 DNA). All cell extracts were prepared following scrape 
harvesting of 293T cells using CHAPS lysis buffer (1% CHAPS detergent, 150mM NaCl, 
50mM Tris pH 7, 5mM EDTA), For immunoprecipitation, 400ug of protein was incubated 
in 400uL of total CHAPS buffer and incubated with indicated affinity matrix (Anti-FLAG 
beads) for 1 h at 4 °C. Following incubation, the matrix was washed three times in CHAPS 
buffer and then SDS loading buffer was added directly to washed matrix, boiled, and 
loaded directly into the wells of a PAGE gel.  
 
Immunofluorescence 
HEK 293T or HeLa cells were transfected with FLAG-UBQLN1, dry seeded on round 
coverslips in 12 well plates and 48 hours post transfection were fixed with 4.0% 
paraformaldehyde in PBS for 15-20 min and then permeabilized with 0.1% Saponin for 60 
minutes at room temperature. Cells were rinsed thrice with PBS, and then incubated 




washes with PBS, cells were then incubated with Alexa Fluor 488 goat anti-rabbit IgG 
(1:300, A11034 Molecular Probes, Invitrogen detection technologies, Eugene, OR, USA). 
After incubation with secondary antibody for 60 minutes, cells were rinsed with PBS and 
incubated with Alexa Fluor 568 Phalloidin (1:1000 A12380: Life technologies Eugene, OR, 
USA) for 10 minutes. After 3 successive washes with PBS, nuclei were counterstained 
with DAPI (1:000) for 10 min at room temperature followed by three washes (5–10 min 
each) with PBS. The cells were then imaged under Nikon A1R confocal laser scanning 
microscope. Multiple images were acquired from multiple experiments and representative 
images are presented. 
 
Radioligand Binding Assay 
Cells were incubated for 2 hours with increasing concentrations (0.001 nM to 0.05 nM) of 
125I-IGF1 (Perkin Elmer, Waltham, MA) at 4°C in binding buffer (DMEM/20 mM 
HEPES/0.1% BSA, pH 7.3). Two fractions were collected – total ligand binding (125I-IGF1) 
and non-specific binding (mixture of radiolabeled and non-radiolabeled ligand). After 2 
hours incubation on ice, cells were washed four times with binding buffer to remove 
unbound radioligand. Solubilizing buffer (0.5N SDS, 1N NaCl) was used to collect the cells 
and the radioactivity of each fraction was determined using a Beckman Coulter (Brea, CA) 
gamma counter. Specific binding for each concentration of 125I-IGF1 was calculated by 
subtracting non-specific binding from total binding for that concentration of 125I-IGF1. Bmax 
and Kd (cpm) were calculated by PRISM analysis based on Specific Binding values (non 
specific subtracted by total binding). Bmax (mmol), Kd (nmol/L) and number of receptors 









Percoll Gradient Density Centrifugation 
A549 cells expressing UBQLN1 shRNA (shUBQLN1 and shControl) (15×106 cells) were 
seeded onto 15 cm2 plate and cultured for 12 hours in serum-free conditions before 
stimulating with IGF1 for 1 hour followed by harvesting, lysing and loading onto a Percoll 
gradient to fractionate organelles makers based on relative density. Detailed methods are 
described by Kornilova and Sorkin (Kornilova, Sorkina, Beguinot, & Sorkin, 1996). These 




A549 cells expressing UBQLN1 shRNA (U1KD#1, U1KD#2 and control) (2 × 104 cells) 
were seeded onto 96 well plate and cultured for 3 days under 3 different conditions-- 
serum-free media, serum-free media supplemented with IGF1 (50ng/ml) or serum-free 
media supplemented with Linsitinib (1uM). Cell viability was assessed by Alamar Blue 
assays on each day. Data were normalized to control shRNA cells in serum-free condition. 
These experiments were performed 2 separate times and data here are representation of 
a single experiment.  
 
Transwell Migration 
A549 cells expressing UBQLN1 shRNA (shUBQLN1, shUBQLN2 and control) 
(2.5 × 104 cells) were seeded onto the wells of Transwell filters in a 12-well plate, 
according to the manufacturer's instructions (Corning). The Transwell setup consisted of 
an upper chamber (conditions of serum-free media, serum-free media supplemented with 
IGF1 (50ng/ml) or serum-free media supplemented with Linsitinib (1uM)) that was placed 
onto a lower chamber (RPMI media enhanced with 10% FBS, creating a chemotactic 




cells that migrate towards serum. After incubation at 37C and 5%CO2 for 24 hours, the 
inserts were examined for migration in the above 3 conditions. Results were compiled as 
the mean and standard error of 3 separate experiments. 
 
Total RNA Extraction and Real Time PCR 
Total RNA was isolated from the A549 cells after washing twice with phosphate-buffered 
saline (PBS) and harvested with E.Z.N.A Total RNA Extraction Kit (Omega, USA) 
according to the supplier’s protocol followed by DNAse digestion. RNA quality and quantity 
were determined by photometry. Total RNA (1μg) was reverse-transcribed to cDNA using 
Thermo Script RT–PCR kit. Briefly, RNA was reverse-transcribed in cDNA with oligo (dT) 
primers and 200 U of Superscript II (Invitrogen) following manufacturer’s instructions. 
Real-time analysis for IGF1R, INSR, IGF1, IGF2, Insulin and normalizing gene human 
β2Microglobulin or β-Actin was performed using SYBR Green Master Mix as per the 
manufacturer’s instruction (Applied Biosytems). This technique continuously monitors the 
cycle-by-cycle accumulation of fluorescently labeled PCR product. Briefly, cDNA 
corresponding to 25 ng of RNA served as a template in a 10μl reaction mixture containing, 
0.2 nM (each) primer, and 5μl FastStart DNA Master SYBR Green mix (ABI). Samples 
were loaded into 96-well plate format and incubated in the fluorescence thermocycler 7500 
(ABI System). Initial denaturation at 95 °C for 10 min was followed by 45 cycles, each 
cycle consisting of 95 °C for 15 s, touchdown of 1 °C/cycle from the primer-specific start 
to end annealing temperatures for 5 seconds, and 60 °C for 10 seconds. The primer 
sequences used for specific genes are listed in Table. All quantifications were normalized 
to the housekeeping HPRT gene, which showed a very stable expression in A549 cells. 
Fold changes in gene expression were calculated using 2−ΔΔCT method. Following are the 
primer sequences used for the reaction: 

























IGF1R-beta (CST#3027), IGF1R Beta XP (CST#9750), p-IGF1R beta (CST #3918), AKT 
(CST #9272), p-AKT (CST#9271); Tubulin #B512 (Sigma); GAPDH #FL335 (Santa Cruz); 
Actin (Sigma#A5316), Ubiquilin1 (CST#14526); Anti-FLAG Affinity Gel (Sigma A2220), 
INSR (CST #3025), FLAG, EEA1, TfnR 
 
RNAi Sequences  
All RNAi (siRNAs) used for study were ordered from Thermo Fisher Scientific Biosciences 
Inc. Lafayette, CO 80026, USA and transfections were done using Dharmafect1 as per 
the supplier’s instructions. 











The Ubiquilin (UBQLN) family of proteins (UBQLN1-4, UBQLN-L) is 
evolutionarily conserved and structurally similar. UBQLN1 is ~63 kDa protein and all 
its family members have 3 functional domains: ubiquitin- like domain (UBL) at the N-
terminus, ubiquitin- associated domain (UBA) at the C-terminus and STI chaperone-
like regions in the middle (Fig. 1A). UBQLN1 is ubiquitously expressed in all tissues. 
Mutations and loss of the UBQLN1 gene have been detected in a variety of disorders 
ranging from neurodegenerative disorders like Alzheimer’s disease (1) to cancers like 
non-small cell lung adenocarcinoma (2). Initially, UBQLN1 was discovered as a protein 
that interacted with IAP (CD47) in ovarian cancer cells, and upon loss, increased cell 
spreading (3). However, since then UBQLN1 has been largely studied in the context 
of neurodegenerative disorders and protein quality control. UBQLN1 assists in 
proteasomal degradation of ubiquitinated substrates and also participates in ERAD 
(Endoplasmic Reticulum Associated Degradation) (2), autophagy (4,5), apoptosis (6) 
and receptor trafficking (7). As a UBL-UBA protein, UBQLN1 is hypothesized to bind 
to poly-ubiquitin chains of substrate through its UBA domain and shuttle it to the 19s 
proteasome via its UBL-S5a cap interaction. The central region of UBQLN1 consists 
of STI domains that are called so because of their similarity to STI-1 proteins (STress 
Inducible proteins or Hsp70-Hsp90 organizing protein). This region acts as a co-
chaperone and mediates hydrophobic interactions with other proteins (8,9). There is 




have reported that UBQLN1 facilitates proteolysis of substrates that it binds. Dsk2p, 
the yeast homolog of UBQLN1, forms a trimeric complex with Rad23 and Cdc48 and 
enables degradation of misfolded proteins via the proteasomal system (10). In human 
cells, the UBL domain of UBQLN1 has been shown to regulate degradation of 
misfolded proteins like Ataxin3, a deubiquitinase enzyme, HSJ1a, a protein that 
stimulates activity of Hsp70, and EPS15, a protein important in endosomal trafficking 
(11). UBQLN1 expression aids in poly-ubiquitination of viral polymerase NS5B, 
decreasing its half-life in HCV infected hepatocytes (12). In contrast, UBQLN1 
stabilizes proteins like Presenilin1/2 (13,14), IκBα (15), and BCLb (16) when bound to 
them. These data indicate that UBQLN1 either stabilizes or facilitates degradation of 
substrates that it binds to. The signal that determines this fate is unknown.  
 In this study, we aimed to understand characteristics of substrates that bind to 
UBQLN1 and whether the nature of UBQLN1-substrate interaction decides the fate of 
substrates – stabilization or degradation. We show that Ubiquilin interacts with multiple 
substrates through its STI or UBL domains. We also show that UBQLN1 is capable of 
forming dimers and continues to interact with proteins in its dimerized form. We have 
previously published that UBQLN1 interacts with the anti-apoptotic BCL2 protein BCLb 
and stabilizes it in the cytoplasm. Here, we have used BCLb as a model to characterize 





Cellular distribution of UBQLN1 
HPL1D, non-transformed lung epithelial cells and HeLa cells transfected with FLAG-
tagged UBQLN1 were examined for UBQLN1 staining by indirect 
immunofluorescence. Both endogenous (green in HPL1D cells) and exogenous 
UBQLN1 (red in HeLa cells) are ubiquitously expressed in the cytosol (Fig. 2A). 
However, in both these conditions, UBQLN1 is distinctly absent from nuclei and 
vacuolar compartments. To further examine if UBQLN1 associated with specific 
compartments of cells, we collected supra-nuclear lysates from Hela cells and loaded 
onto Percoll for density gradient centrifugation of proteins (Fig. 2B). There was slightly 
higher detection of UBQLN1 towards lower density gradients but overall, UBQLN1 
seems to be expressed throughout the cytoplasm and possibly associates with multiple 
cellular compartments and organelles. Na-K-ATPase, an enzyme found in cell 













Figure 2: Cellular Distribution of UBQLN1 
A: Confocal microscopy images of indirect immunofluorescence staining of 
endogenous UBQLN1 (green) in normal lung epithelial HPL1D cells and 
over-expressed FLAG-tagged UBQLN1 (red) in HeLa cells. Both 
endogenous and exogenous UBQLN1 are ubiquitously expressed in the 
cytosol. However, in both these conditions, UBQLN1 is distinctly absent from 
nuclei and vacuolar compartments.  
B:	Supra-nuclear lysates from Hela cells were loaded onto Percoll for density 
gradient centrifugation of proteins. Overall, UBQLN1 was detected in all 
fractions with slightly higher expression towards the lower density gradients. 
Na/K-ATPase, an enzyme found in cell membrane of all animal cells is used 
as a control protein for lower density gradient fractions.  Density fractions 






UBQLN1 non-selectively interacts with diverse ubiquitin linkages through its 
UBA domain  
Our previous work suggested that UBQLN1 interacts with mono-ubiquitinated BCLb 
(16). However, previous work by Feng et al (15) and Zhang et al (17) showed that UBA 
domain of UBQLN1 is also capable of associating with poly- ubiquitin chains. 
Therefore, we investigated if UBQLN1 interacts with specific ubiquitination linkages on 
substrates. We engineered constructs of UBQLN1 missing individual domains (Fig. 
3A). Cells were transfected with empty vector (EV), FLAG UBQLN1WT or deletion 
constructs of UBQLN1 (Fig. 3A) and HA-UbWT (Ubiquitin) (Fig. 3B,C). FLAG-UBQLN1 
was immunoprecipitated and interaction with HA-Ubiquitin was examined. We 
confirmed that the UBA domain of UBQLN1 interacts with ubiquitin as constructs 
missing the UBA domain, namely UBQLN1112X and UBQLN1DUBA fail to pull down HA-
Ubiquitin. Next, we performed a similar experiment using our individual domain 
deletion constructs (Fig. 3A) and confirmed that ΔUBA does not interact with ubiquitin. 
Interestingly, ΔSTI-4 construct also failed to pull down ubiquitin probably because of 
STI-4 domain’s close proximity to the UBA domain such that when STI-4 is deleted, it 
directly impacts UBA domain’s ability to interact with ubiquitin. Next, we tested for 
preference of the UBA domain of UBQLN1 for diverse ubiquitin linkages. We used 
constructs of HA-UbiqutinWT that have all Lysines (K) mutated to Arginine (R) except 
one, for example, HA-UBQTNK33 has all K’s mutated to R except K33 and therefore 
overexpression promotes formation of K33 ubiquitin chains on substrates. K0 indicates 
all K’s have been mutated to R and this ubiquitin molecule can be conjugated to 
substrate (mono- ubiquitination), but is not capable of forming ubiquitin chains. Results 
show that UBQLN1 is capable of interacting with WT, K33-, K48-, K63- poly-ubiquitin 
chains and mono-ubiquitinated residues (Fig. 3D). Based on these data and literature 
(17) we conclude that UBQLN1 non-selectively interacts with diverse ubiquitin linkages 








Figure 3: UBQLN1 interacts non-preferentially with diverse ubiquitin linkages 
through its UBA domain.  
(A) Schematic of UBQLN1WT and engineered domain deletion constructs missing 
individual domains. (B,C), 293T cells were transfected with empty vector (EV), 
FLAG-UBQLN1WT, domain deletion constructs of UBQLN1 and HA-UbiquitinWT. 48 
hours post transfection, cells were lysed and Western Blot analyses were performed 
with the indicated antibody. Where indicated, immunoprecipitation with anti-FLAG 
conjugated agarose beads was performed. UBQLN1WT interacts with ubiquitin but 
UBQLN1112X and UBQLN1ΔUBA (both missing UBA domain) lose this interaction. 
Therefore, UBQLN1 interacts with ubiquitin through the UBA domain. (D) 293T cells 
were transfected with FLAG-UBQLN1WT and constructs of HA-UbiquitinWT that have 
all Lysines (K) mutated to Arginine (R) except one for example, HA-UbiquitinK33 has 
all K’s are mutated to R except K33 and therefore overexpressing and promoting 
formation of K33 ubiquitin chains on substrates. K0 indicates all K’s have been 
mutated to R and this ubiquitin molecule is can only conjugate to the substrate 
(mono-ubiquitination) and is incapable for forming ubiquitin linkages. UBQLN1 
interacts with WT, K33-, K48-, K63- poly-ubiquitin chains and K0 mono-ubiquitinated 






Recognition of the transmembrane domain of BCLb by STI-1/2 domains of 
UBQLN1 sequesters BCLb in the cytosol 
Recently, Itakura et al (18) found that the UBQLN4 recognizes the transmembrane 
domain of mitochondrial protein OMP25. We have previously shown that UBQLN1 
interacts with mitochondrial protein BCLb and stabilizes it in the cytosol. Here, we 
investigated the domain of UBQLN1 required for interaction with BCLb our deletion 
constructs of UBQLN1. We identified STI-1 and STI-2 domains on UBQLN1 as critical 
for interacting with BCLb. 293T cells were transfected with empty vector (EV), FLAG-
UBQLN1WT, FLAG-UBQLN1 domain deletion constructs, MYC-BCLbWT or MYC-
BCLbDTM. Where indicated, immunoprecipitation with anti-FLAG beads was performed 
and probed for MYC-BCLb by Western Blot analyses. STI-1 and STI-2 domains of 
UBQLN1 are required for interaction with BCLb (Fig. 4A). UBQLN1WT and all domain 
deletion constructs except ΔUBA, interact with multi mono-ubiquitinated BCLb, 
indicated by the ladder-like pattern at higher molecular weights. Thus, the UBA domain 
of UBQLN1 is obligatory to interact with ubiquitin on BCLb. Next, we determined that 
TM domain is essential for UBQLN1 to recognize and interact with BCLb. These data 
suggest a potential 2-fold interaction between UBQLN1 and BCLb such that that the 
STI domains of UBQLN1 associate with the TM domain of BCLb and the UBA domain 
associates with the ubiquitin on BCLb (Fig. 4B). Previously, we have shown that 
UBQLN1 interacts with BCLbWT and sequesters it in the cytosol. As we determined that 
UBQLN1 needs an intact TM domain of BCLb to interact with it, we tested if UBQLN1 
alters the location of the BCLbDTM. We performed subcellular fractionation by 
differential centrifugation to determine changes in cellular location of BCLbDTM. Results 
show that UBQLN1 does not recognize BCLbDTM, and therefore, does not interact with 
it and has no effect on its cellular location (Fig. 4C). Our data confirm results by Itakura 
et al (18) that UBQLN proteins are capable of recognizing transmembrane domains of 












Figure 4: Recognition of the transmembrane domain of BCLb by STI-
1/2 domains of UBQLN1 sequesters BCLb in the cytosol 
The transmembrane domain of BCLb is recognized by STI-1/2 domains of 
UBQLN1 and stabilizes BCLb in the cytoplasm. 293T cells were transfected 
with empty vector (EV), FLAG-UBQLN1WT, or FLAG-tagged domain 
deletion constructs, MYC-BCLbWT or MYC-BCLbΔTM. Forty-eight hours post 
transfection, cells were lysed and Western Blot analyses were performed 
with the indicated antibody. Where indicated, immunoprecipitation with anti-
FLAG conjugated agarose beads was performed to determine interaction 
between UBQLN1 and BCLb proteins. (A) STI-1/2 domains of UBQLN1 are 
required to interact with BCLb. (B) BCLbΔTM does not interact with UBQLN1. 
A functional transmembrane domain on BCLb is required for UBQLN1 to 
recognize and interact with it. (C) 293T cells expressing BCLbWT or 
BCLbΔTM with EV or FLAG-UBQLN1, were subjected to subcellular 
fractionation, followed by Western Blot analyses. Cells were fractionated 
into cytosolic (c) and membranes (m). VDAC1, a membrane bound protein, 
and Tubulin, a cytoplasmic protein were used to document the validity of the 
fractionations. UBQLN1 does not interact with BCLbΔTM and therefore, does 
not alter the location of BCLbΔTM, as it is unable to recognize it. (Data are 






Interaction of UBQLN1 with BCLb is independent of ubiquitination of BCLb 
We showed above that the UBA domain which interacts with ubiquitin is dispensable 
for interaction of UBQLN1 with BCLb. BCLb has 4 lysines that can be potentially 
ubiquitinated (16) and therefore, we investigated whether ubiquitination of BCLb 
played a role in its interaction with UBQLN1. We generated a construct of BCLb 
(BCLbK0) in which all 4 lysines were mutated to arginine. We tested whether BCLbK0 is 
capable of being ubiquitinated and whether UBQLN1 interacts with non-ubiquitinated 
BCLb. Cells were transfected with BCLbWT, lysine-less BCLb (BCLbK0), HA-
UbiquitinWT, lysine-less Ubiqutin (HA-UbiquitinK0) and FLAG- UBQLN1. Where 
indicated, immunoprecipitation with either anti-FLAG or anti-HA conjugated beads was 
performed to determine UBQLN1- or Ubiquitin-interacting complexes, respectively as 
previously shown. BCLbWT gets mono- ubiquitinated on several of its lysine residues 
as observed by the ladder-like pattern of ubiquitination in BCLbWT in the presence of 
UbiquitinWT. BCLbK0 does not get ubiquitinated. Non-ubiquitinated BCLbK0 also fails to 
be pulled down with anti HA-Ubiquitin antibody. Immunoprecipitating with anti-FLAG 
beads showed that UBQLN1 interacts with both BCLbWT and BCLbK0 implying that 
UBQLN1 interacts with BCLb in its ubiquitinated (BCLbWT) and non- ubiquitinated 
(BCLbK0) forms. These data indicate interaction of UBQLN1 with BCLb is independent 






                                                                                                                           
Figure 5: Interaction of UBQLN1 with BCLb is independent of 
ubiquitination of BCLb.  
(A) Schematic of mono-ubiquitination on BCLb. Lysine residues are 
not mapped, picture is for representation purposes only. (B) 
Schematic of poly-ubiquitination of BCLb. Lysine residues are not 
mapped, picture if for representation purposes only.  (C) 293T cells 
were transfected with BCLb (MIG-BCLbWT), lysine-less BCLb (MIG-
BCLbK0), wild-type Ubiquitin (HA-UbWT), lysine-less Ubiquitin (HA-
UbK0), and FLAG-UBQLN1WT. Forty-eight hours post transfection, 
cells were lysed and Western Blot analyses were performed with the 
indicated antibody. Where indicated, immunoprecipitation with either 
anti-FLAG or anti-HA conjugated agarose beads was performed to 
determine FLAG-UBQLN1 or HA-Ubiquitin interacting complexes, 
respectively. BCLb gets ubiquitinated on its lysine residues as seen 
by failure to pull down BCLbK0 by HA-Ubiquitin. UBQLN1 interacts 
with both BCLbWT and BCLbK0 implying that UBQLN1 interacts with 
ubiquitinated (WT) and non-ubiquitinated (K0) BCLb as observed by 
the ladder-like pattern of ubiquitination in BCLbWT in the presence of 
HA-Ubiquitin. Note; HA-tag adds ∼1 kDa to the molecular weight of 
Ubiquitin. (Data are from one experiment). (D) Schematic showing 
UBQLN1 primarily interacts with BCLb through its STI domains and there 
may exist a secondary association between UBQLN1’s UBA domain and 






Ubiquilin1 stabilizes BCLbWT after translational and proteasomal inhibitionWe 
We have previously shown (16) that BCLb gets completely degraded within 16 hours 
after blocking new protein synthesis by CH. However, in the presence of UBQLN1WT, 
it is stabilized and protected from degradation. We wanted to determine whether 
ubiquitination of BCLb plays a role in its stability. Cells were transfected with BCLbWT 
or BCLb engineered to lack all its four lysine residues (BCLbK0) or empty vector (EV). 
Cells were treated with the indicated translational (CH) and proteasomal (MG132, 
Epoximide, Bortezomib) inhibitors for 16 hours. GFP is used as an expression control 
since GFP is expressed from the same mRNA as BCLb following an internal ribosomal 
entry sequence. (Fig.7A). BCLbWT was completely degraded in the presence of CH for 
16 hours while BCLbK0 expression was completely stable. This may indicate that CH 
induced degradation of BCLbWT is dependent on its lysines and therefore its 
ubiquitination, whereas degradation induced by proteasomal inhibition is independent 
of ubiquitination. UBQLN1 was co- transfected with BCLbWT or BCLbK0 to test its effect 
on BCLb stability (Fig. 7B). Presence of UBQLN1 stabilized expression of BCLbWT 
following both translational inhibition and proteasomal inhibition. Thus, UBQLN1 
generally stabilizes BCLbWT. Furthermore, UBQLN1 also stabilizes BCLbK0 from 
proteasome inhibition- induced degradation. Immunoprecipitating with FLAG antibody 
demonstrated that UBQLN1 interacted with both BCLbWT and BCLbK0 under conditions 
of proteasomal inhibition by MG132 or translational inhibition by CH, implying that 
primary interaction with BCLb is not lysine mediated (Fig. 7B). We then tested the 
effect of deletion constructs of UBQLN1 on stability of BCLbWT (Fig.7C). UBQLN1DUBA 
interacts with BCLb, but fails to prevent loss of BCLbWT when exposed to CH. We 
conclude that interaction of UBQLN1 with ubiquitin is dispensable for interaction with 
BCLb, but secondary interaction with ubiquitin on substrates is essential for its 
stabilization. As the transmembrane domain of BCLb is required for interaction with 




BCLbDTM is less stable than BCLbWT. However, an interesting observation is that BCLb 
lacking the transmembrane domain is the only construct that is stabilized following 
inhibition of the proteasome by MG132. Further, presence of UBQLN1 doesn’t not alter 
stability of BCLbDTM (Fig. 7D), as it is unable to interact with it. Therefore, interaction 
between UBQLN1 and BCLb is independent of ubiquitination of BCLb but is required 











Figure 6: Schematic of mechanism of stabilization of BCLb by UBQLN1.  
(A) Steady state expression of BCLb molecules in cells. BCLb is distributed in the 
cytoplasm and anchored in the mitochondrial outer membrane. (B) BCLb protein 
expression is lost within 16 hours of blocking new protein synthesis or blocking 
the proteasome. (C) When UBQLN1 is overexpressed, loss of BCLb due to 
mechanisms in B, is prevent and BCLb expression is stabilized overall. (D) 








Figure 7: UBA domain of UBQLN1 is responsible for stabilization of 
BCLbWT.  
293T cells were transfected with MIG-BCLbWT, MIG-BCLbWT, MIG-BCLbΔTM, 
FLAG-UBQLN1WT, domain deletion constructs FLAG-UBQLN1112X and 
FLAG-UBQLN1ΔUBA as indicated. 36 hours post transfection, cells were 
treated with the indicated inhibitor for 16 hours; vehicle (-), translational 
elongation inhibitor Cycloheximide (CH) and proteasomal inhibitors MG132 
(MG), Epoximicin (Epoxi.) and Bortezomib (Bortez.). Cells were lysed and 
Western Blot analyses were performed with the indicated antibody. (A) 
Stability of BCLbWT and BCLbK0 was tested in the presence of UBQLN1, 
when exposed to the indicated inhibitors for 16 hours. (B) Experiment was 
performed as in A but in the presence of UBQLN1. As seen in A, expression 
of BCLbWT is lost upon exposure to CH for 16 hours, but in the presence of 
UBQLN1, it is stabilized. Loss of BCLbWT seen with proteasomal inhibitors 
is also rescued by the presence of UBQLN1. UBQLN1 also prevents loss of 
BCLbK0 seen with MG132. (C) Experiment was performed as in A in the 
presence of CH and domain deletion constructs of UBQLN1 and we 
mapped the UBA domain to be responsible for stabilizing BCLbWT. Both 
UBQLN112X and UBQLN1ΔUBA failed to prevent loss of BCLbWT. (D) Stability 
of BCLbΔTM was tested similar to BCLbWT and BCLbK0. BCLbΔTM is generally 
less stable than BCLbWT and presence of UBQLN1 does not alter its 






IGF1R, ESYT2 and BAG6 are newly identified substrates of UBQLN1. Interaction 
of UBQLN1 with IGF1R and ESYT2 is STI-mediated while with BAG6 and PSMD4 
is UBL-mediated 
We characterized the nature of interaction between UBQLN1 and BCLb using BCLb 
as a model substrate. We wanted to determine if these interaction characteristics could 
be generalized to other substrates of UBQLN1. Our IP/MS data (not shown) identified 
insulin-like growth factor 1 receptor (IGF1R), a cell surface receptor tyrosine kinase, 
Extended Synaptogammin-2 (ESYT2), a calcium regulated intrinsic membrane protein 
and BAG6, a protein involved in proteasomal degradation machinery of misfolded 
proteins, as potential interacting partners of UBQLN1. We mapped the interaction of 
UBQLN1 with IGF1R and ESYT2 to the STI domains and BAG6 and PSMD4 (or S5a, 
26S proteasomal subunit and known interacting partner of UBQLN proteins) to the 
UBL domain (Fig. 8A). Like with BCLb, STI domains of UBQLN1 are required for 
interaction with IGF1R and ESYT2 as UBQLN1112X missing the STI domains is unable 
to interact with these 2 substrates. Interaction of UBQLN1 with BAG6 and PSMD4 is 
purely UBL mediated as detected with all 3 constructs, UBQLN1WT, UBQLN1112X and 
UBQLN1DUBA that have the UBL domain intact. Like BCLb, UBQLN1 interacts with 
IGF1R and ESYT2 via its STI domains but needs the UBA domain to stabilize it after 
proteasomal inhibition 
Once we identified additional substrates that interact with different domains of 
UBQLN1, we wanted to determine substrate stability with specific interaction domains 
(Fig. 8B). We performed stability experiments with IGF1R, ESYT2, PSMD4 and BAG6 
as we did with BCLb. Cells were transfected with empty vector (EV), UBQLN1WT, 
UBQLN1112X or UBQLN1DUBA and exposed to CH or MG132 for 48 hours. Our results 
show that IGF1R expression decreased in the presence of CH, which blocks new 
protein synthesis. IGF1R expression also decreased in response to proteasomal 




independent pathways (Fig. 8C). In the presence of UBQLN1DUBA, degradation of 
IGF1R through these non-proteasomal pathways seemed to be accelerated indicating 
that the presence of UBA domain prevents the loss of expression of IGF1R with 
MG132 exposure. We found strikingly similar data when we tested stability of another 
membrane protein ESYT2. UBQLN1DUBA failed to prevent loss of IGF1R and ESYT2 
under proteasomal blockade suggesting that the UBA domain of UBQLN1 is essential 
in stabilizing IGF1R and preventing its degradation through non-proteasomal 
pathways. PSMD4 and BAG6 levels seemed steady and unchanging under both CH 
and MG132 exposure and the presence of UBQLN1WT, UBQLN1112X or UBQLN1DUBA 
did not alter their expression suggesting that substrate interactions of UBQLN1 that 


















Figure 8: Fate of substrates targeted by UBQLN1 is dependent on 
interaction of the substrate with specific domains of UBQLN1.  
(A) 293T cells were transfected with FLAG-tagged UBQLN1 (MIG-PLIC1) 
and an empty vector control (EV) followed by immunoprecipitation and 
analysis by mass spectrometry. The data from one representative 
experiment is shown. The number of unique peptides identified for each 
UBQLN1-interacting protein is shown. (B) 293T cells were transfected with 
FLAG-tagged deletion constructs of UBQLN1 followed by 
immunoprecipitation by FLAG antibody and Western Blot analysis. Like 
BCLbWT, STI domains of UBQLN1 are required to interact with IGF1R and 
ESYT2 as UBQLN1112X missing the STI and UBA domains do not interact 
with these two substrates. UBQLN1WT, UBQLN1112X, and 
UBQLN1ΔUBA interact with both PSMD4 and BAG6 indicating that this 
interaction is UBL mediated. (C) Stability of IGF1R, ESYT2, PSMD4, and 
BAG6 were tested upon CH and MG132 exposure for 48 h as with BCLb in 
Fig. 4. In the absence of the UBA domain (UBQLN1ΔUBA), IGF1R and ESYT2 
expression are lost upon proteasomal inhibition with MG132. PSMD4 and 
BAG6 expression are unchanged after 48 h of CH and MG132 and the 
presence of UBQLN1WT, UBQLN1112X, or UBQLN1ΔUBA does not affect their 





UBQLN1 is capable of homodimerization through its STI-4 domains 
Several studies have reported that UBQLN1 is capable of homodimerizing (19) 
and UBQLN2 heterodimerizes with UBQLN4 (20). Feng (15) and Ford (19) showed 
that the middle region with STI domains is responsible for dimerization while other 
studies suggest a UBL-UBA dependent interaction. We investigated the presence of 
UBQLN1 dimers and determined if it is capable of interacting with substrates in its 
dimerized state. Cells were transfected with empty vector (EV), FLAG-UBQLN1WT or 
deletion constructs of FLAG-UBQLN1WT and MYC-UBQLN1WT. Results show MYC-
UBQLN1 was pulled down when we immunoprecipitated FLAG- UBQLN1 and the STI 
domains located between amino acid 112 and 542 in UBQLN1 are required for this 
interaction to take place (Fig. 9A). We mapped this interaction specifically to the STI-
4 domain (Fig. 9B). Our data do not indicate a UBL- UBA interaction, as recently 
suggested (18). These data indicate that FLAG-UBQLN1 and MYC-UBQLN1 
associate with each other. However, whether this complex is between 2 or more 
molecules of UBQLN1 cannot be answered by these data. It is possible that UBQLN1 
participates in a multimeric complex with other molecules of UBQLN1 or its isoforms. 
Next, we investigated if interaction with substrate disrupted UBQLN1 dimers (Fig. 9C). 
Results show that endogenous substrates of UBQLN1 (IGF1R; lanes 2,6,7) or 
introducing exogenous substrates (BCLb and IGF1R; lanes 7 and 8 respectively) do 
not alter the amount of dimerized UBQLN1 protein as witnessed by a consistent 
amount of MYC-UBQLN1 being pulled down with FLAG-UBQLN1. This suggests that 



































Figure 9: UBQLN1 is capable of homodimerization through its STI-
4 domains 
UBQLN1 dimerizes via its STI-4 domains. A total of 293T cells were 
transfected with empty vector (EV), MYC-UBQLN1WT, FLAG-
UBQLN1WT, domain deletion constructs of UBQLN1 MYC-
UBQLN1WT as indicated. Forty-eight hours post transfection, cells were 
lysed and Western Blot analyses were performed with the indicated 
antibody. Where indicated, immunoprecipitation with anti-FLAG 
conjugated agarose beads was performed to determine interaction. (A) 
FLAG-UBQLN1WT interacts with MYC-UBQLN1 and the STI domains 
located between amino acid 112 and 542 are required for this interaction 
to take place. (B) Domain deletion constructs map the dimerization to 
the STI-4 domain. (C) The level of dimerization of UBQLN1 proteins 
remain unchanged in the presence of endogenous substrates (IGF1R; 
lanes 2,6,7) and introducing exogenous substrates (BCLb and IGF1R; 






In this study we aimed to identify characteristics of UBQLN1-substrate 
interaction that lead to proteostasis of the substrate. Using BCLb as a model substrate, 
our data challenge the dogma that the primary function of UBQLN1 is to facilitate 
degradation of misfolded proteins. We undertook a systematic approach to investigate 
indicators of stabilization of BCLb as a substrate of UBQLN1.  
`First, we investigated whether diverse ubiquitin linkages on proteins that 
interact with UBQLN1 play a role in its proteostasis. We used domain deletion 
constructs of UBQLN1 and confirmed that its UBA domain associates with ubiquitin 
(Fig. 3B,C). Further, we found no difference in the type of ubiquitin linkage recognized 
by the UBA domain when we overexpressed HA-Ubiquitin constructs capable of 
forming K33, K48, K63 poly-ubiquitin chains as well as mono-ubiquitinating substrates 
(Fig. 3D). Our data complement findings by Zhang et al (17) that the UBA domain of 
UBQLN1 binds to both monomeric ubiquitin as well as poly-ubiquitin chains. Feng et 
al (15) also reported that the UBA domain is capable of interacting with poly-ubiquitin 
chains but did not test for interaction with monomeric ubiquitin. We have previously 
shown that BCLb lysine residues get mono- ubiquitinated and van de Kooji et al (21) 
showed that one out of its 4 lysines, K128 residue on BCLb is capable of forming K48 
poly-ubiquitin chains which signals BCLb for proteasomal degradation. Our data 
indicate that the UBA domain non-selectively interacts with ubiquitin on BCLb, 
prevents binding of additional ubiquitin molecules that signal BCLb for proteasomal 
degradation (Fig. 3,4,7). Thus, unlike K48 ubiquitination, which specifically signals for 
degradation or K63 ubiquitination, which signals for trafficking, the ubiquitin code on 
UBQLN1’s substrates does not decide its fate. To further understand the 
characteristics of UBQLN1-BCLb interaction, we mapped the location of their 
interaction on both proteins. We identified the STI-1/2 domains on UBQLN1 and 




(Fig. 4A,B). UBQLN1 most likely recognizes the TM domain as BCLb is being 
translated and binds to it, stabilizing BCLb in the cytoplasm. We performed several 
stability experiments of BCLb in the presence of translational and proteasomal 
inhibitors (Fig. 7). BCLbWT is degraded completely following 16 hours of cycloheximide 
(CH) treatment. UBQLN1 prevents loss of BCLb implying that their physical interaction 
protects BCLb from degradation. In the presence of CH, UBQLN1DUBA interacts with 
BCLb via its STI-1/2 domains (Fig. 4A) but fails to stabilize it (Fig. 7C) indicating that 
the UBA domain is required to stabilize BCLb. Lysine-less BCLb (BCLbK0) is more 
stable than BCLbWT at 16 hours post cycloheximide treatment as our group (2009) and 
van de Kooji et al in 2013 have previously shown. Added stability of BCLbK0 over 
BCLbWT suggests that degradation is dependent on its lysines and therefore, likely its 
ubiquitination. van de Kooji et al showed that BCLb gets K48 poly-ubiquitinated on its 
K128 residue, which signals BCLb for proteasomal degradation. We hypothesize that 
when UBQLN1 is overexpressed, its UBA domain acts as a ubiquitin receptor and 
blocks chain elongation past mono-ubiquitination, thus preventing formation of K48 
ubiquitin chains and degradation.  
We tested whether UBQLN1-induced stability observed with BCLb could also 
be a phenomenon for other substrates of UBQLN1. Our IP/MS data (not shown) and 
IP/WB data (Fig. 8A) indicate that UBQLN1 interacts with insulin-like growth factor 1 
receptor (IGF1R) and Extended Synaptogammin-2 (ESYT2) and like BCLb, it interacts 
with these 2 membrane proteins through its STI domains. We tested stability of IGF1R 
and ESYT2 (Fig. 5B) under similar conditions as with BCLb (Fig. 7). Upon blocking the 
proteasome with MG132, IGF1R and ESYT2 expression is lost and most likely due to 
degradation via proteasomal-independent pathways. However, in the presence of 
UBQLN1, its loss is prevented. UBQLN1112X and UBQLN1DUBA, both missing the UBA 
domain, fail to protect IGF1R and ESYT2 from degradation. We found that as with 




Recently, Suzuki et al (22), 
showed that UBQLN4 is a 
component of the multi-protein 
proteasomal machinery complex 
involving BAG6 and is responsible 
for recognition of the exposed 
transmembrane domains of newly 
synthesized defective polypeptides, 
eventually leading to their 
proteasomal degradation. We 
found that BAG6 interacts with the 
UBL domain of UBQLN1 and also confirmed PSMD4 to be an interacting partner of 
UBQLN1 (Fig. 8A). As UBL-interacting substrates of UBQLN1, we examined whether 
UBQLN1 binding affects stability of PSMD4 and BAG6 (Fig. 8B). We tested this under 
similar conditions as with BCLb, IGF1R and ESYT2 and found that UBQLN1 does not 
regulate proteostasis of PSMD4 and BAG6 (Fig. 8B). We detected no differences in 
the stability of PSMD4 and BAG6 in the presence UBQLN1WT, UBQLN1112X and 
UBQLN1DUBA when treated with translational or proteasomal inhibitors.  
 Several studies have addressed the role of UBA domain of UBQLN1 in 
stabilizing proteins. Mah et al (14), showed that the UBA domain of UBQLN1 binds 
Presenilin1 (PSEN1) and Presenilin2 (PSEN2) proteins. Massey et al (13) confirmed 
that the UBA domain binds PSEN1/2 and stabilizes these proteins by preventing its 
poly-ubiquitination and proteasomal degradation. Haapaslo et al (23) found that 
overexpression of UBQLN1 stabilized higher molecular weight PSEN1, preventing its 
proteasomal enodproteolysis into smaller N-terminal fragment (NTF) and C-terminal 
	
 
Figure 10: Schematic showing domains of 
substrates UBQLN1 interacts with. 
Substrates with transmembrane domains 
(TM) such as BCLb, IGF1R, ESYT2 are 
stabilized as a result of their interaction. 




fragment (CTF). Other substrates that have been reported to be stabilized by the UBA 
domain of UBQLN1 are p53 and IκBα. Overexpression of UBQLN1/2 prevented 
degradation of p53 by E6AP ubiquitin ligases and IκBα by SCFβTRCP ubiquitin ligase 
complex by blocking additional ubiquitination (24).  
Currently, there is little consensus on the working model of UBQLN1. Our data 
suggest that UBQLN1 is capable of forming dimers via its STI- 4 domain (Fig. 9A,B) 
and is active in its dimerized state as it continues to interact with exogenous BCLb as 
well as endogenous and exogenous IGF1R (Fig. 9C). Our dimerization data confirm 
the mapped location of dimerization shown by Feng (15) (region 441-589) and Ford 
(19) referring to the STI-4 domain (Fig. 9B) as middle regions, i.e. not the N-terminal 
UBL or C-terminal UBA. Hjerpe et al (20) suggest that when not associated with 
substrates, UBQLN2 exists in a UBL-UBA conformation or in an inactive resting state. 
They hypothesize that UBQLN1 opens up and adopts a monomer form to execute its 
function. The UBL-UBA dimer hypothesis subsists because the UBL domain is 
essentially like the ubiquitin molecule, but this domain shares only 4 lysines (K6, K11, 
K27, K48) out of 7 (other three – K29, K33, K63) found in a ubiquitin molecule which 
may contribute to its decreased affinity for the UBA domain. The UBL domain of 
UBQLN1 has been shown to interact with proteins involved in the proteasomal 
	
Figure 11: Current Model: UBQLN1 interacts with substrates through the UBA 
domain and with the proteasome through the UBL domain, directing it for 
degradation.  
Proposed Model:  UBQLN1 interacts with transmembrane proteins through its 
STI domains and secondary association through the UBA domain which stabilizes 




machinery and not just UBA containing proteins. hHR23a is a UBL- UBA protein in this 
class that adopts a closed conformation due to a UBL-UBA interaction When UBL of 
hHR23a binds to the proteasomal subunit S5a, the closed conformation is disrupted 
(25). However, hHR23a has a UBL domain with 11 lysines and 2 UBA domains and 
an XPC region for DNA excision repair. Functionally and location wise, UBQLN1 is 
different from hHR23a. UBQLN1 is a largely cytosolic protein, its UBL domain has 
fewer lysines and one UBA domain and it is probably ill advised to compare functional 
dynamics of UBQLN1 to another UBL-UBA protein.  
Current model of UBQLN1 suggests that UBA domain of UBQLN1 binds to 
poly-ubiquitin chains of substrate and shuttles it to the proteasome via its UBL domain 
for degradation (Fig. 11). Our data indicate that UBQLN1 is capable of interacting with 
substrates via STI domains (BCLb, IGF1R, ESYT2), UBL domain (PSMD4, BAG6), 
and UBA domain (ubiquitin). Kleijnen et al (26) showed that not only the UBL domain 
but also UBA domain on UBQLN2 is capable of directly binding to the S5a cap of the 
proteasome. The ability of the UBA domain to bind the proteasome is unique to UBQLN 
proteins as UBA domain of c-CBL is unable to bind to the proteasome (26). Therefore, 
it is possible that the role of UBQLN1’s UBA domain is to bind to ubiquitin on substrates 
and shield them from being recognized for degradation. The UBA domain of UBQLN1 
is a highly-conserved region across different species and across different isoforms of 
UBQLN1 protein (UBQLN1-4, UBQLNL). For over a decade, UBQLN1 has been 
shown to assist in degradation of proteins but our data suggest that UBQLN1 also 
stabilizes some proteins that it binds to, like BCLb, IGF1R and ESYT2. We propose a 
substrate-stabilization model of UBQLN1 (Fig. 11) such that primary association of 
UBQLN1 with substrate occurs through the STI domains and a secondary association 
through its UBA domain, which leads to stabilization of the substrate. We do not know 
whether primary associations through the UBL domain result in degradation of 




that fate of substrates that UBQLN1 associates with, is interaction-domain specific. All 
3 interacting partners of UBQLN1 stabilized by the UBA domain are membrane 
proteins; BCLb – mitochondrial membrane protein, IGF1R – plasma membrane 
protein, ESYT2 – endoplasmic reticulum/plasma membrane protein (27). We identified 
the transmembrane domain of BCLb to be essential to be recognized by UBQLN1. 
Thus, it is a plausible hypothesis that UBQLN1 recognizes proteins with 
transmembrane domains via its STI domains and stabilizes them via its UBA domain.  
UBQLN1 is a known stress response protein and protects cells from heat shock 
and hypoxic stress (20) and it seems reasonable that UBQLN1 stabilizes crucial 
survival proteins like BCLb, IGF1R and p53 over others. Future work will involve 
characterizing the mechanisms involved in regulation of IGF1R expression and activity 
by UBQLN1 and investigating whether UBQLN1 can be targeted in disorders resulting 
from IGF1R dysregulation.   
	
Figure 12: Models of Interaction of UBQLN1 
This schematic shows hypothetical mechanisms of interaction of UBQLN1 






Insulin-like Growth Factor-1 Receptor 
 IGF1R (Insulin-like Growth Factor-1 Receptor) is a receptor tyrosine kinase 
ubiquitously expressed on cell surfaces of all tissues. Ligand stimulation causes the 
receptor to transmit signals to stimulate cell proliferation, differentiation, survival and 
cellular metabolism. The transmembrane IGF receptors exist in the plasma membrane 
as preformed dimers. Known ligands of IGF1R are IGF-1 (highest affinity), IGF-2 and 
insulin and stimulate IGF1R to activate PI3-AKT and RAS-MAPK downstream 
pathways among others. IGF binding proteins 1-6 (IGFBPs) bind ligands and limit their 
bioavailability and binding to IGF1R (Kurlawala et al., 2017; Yarden, 2001). 
 The IGF pathway has been under investigation as an anti-cancer drug target 
for several decades since IGF1R expression was determined to be crucial for SV40 
large tumor antigen to transform mouse embryonic fibroblasts and its activity was 
discovered to stimulate proliferation in vitro (Sell et al., 1993). IGF1R over expression 
is associated with an increased risk of recurrence of non-small cell lung cancer 
(NSCLC)(Nakagawa et al., 2012). A meta-analysis of 17 studies comprising 3,294 
NSCLC patients concluded that expression of IGF1R positively correlated with 
patients’ smoking status, tumor size and negatively correlated with disease-free 
survival (S. Zhao, Qiu, He, Li, & Li, 2014). Additionally, autocrine and paracrine 
production of IGF1 has been linked to an increased risk of development of breast, 
prostate, and colorectal cancers (Brahmkhatri, Prasanna, & Atreya, 2015; Vigneri et 
al., 2015).  
 Acromegaly or gigantism, an endocrinopathy associated with high circulating 




 cancer (Renehan et al., 2003). In a contrasting condition called Laron dwarfism, 
patients have low circulating IGF1 levels and are resistant to development of cancer 
and diabetes (Laron, 2008).  
 The IGF1R gene does not harbor activating mutations like other receptor 
tyrosine kinases (EGFR and FGFR) and ligand independent activation of IGF1R is not 
known. Still, overexpression of IGF1R is a hallmark finding in lung cancer, malignant 
melanoma, primary breast cancer and pancreatic adenocarcinoma (Brahmkhatri et al., 
2015). This implies that alterations in expression and activity of IGF1R can result from 
anomalous mechanisms of autocrine and paracrine stimulation of receptor, hybrid 
assemblies of IGF receptors, abnormalities in other proteins that regulate its trafficking 
and turnover, and even epigenetic and transcriptional control (Grimberg, 2003). For 
example, mutations in c-Cbl, an E3 ligase, can dysregulate turnover of c-MET, another 
receptor tyrosine kinase, leading to persistent signaling even in the absence of 
receptor overexpression or activating oncogenic mutations (Peschard et al., 2001). 
Currently, the IGF1/IGF1R axis is a major target of research for cancer therapy. 
However, several pharmacological agents -monoclonal antibodies and small molecule 
inhibitors, targeting this axis have failed to show significant benefit on overall survival 
(Janssen & Varewijck, 2014). Unfortunately, expression of IGF1R does not always 
correlate with its cell surface expression and therefore it can be misleading to correlate 
its expression with expected response to therapy. This highlights the role of cellular 
and extracellular factors that modulate the activity of IGF1R directly or indirectly.  
We have identified UBQLN1 as a regulator of IGF1R expression and activity. 
The Ubiquilin family of proteins (UBQLN1-4, UBQLNL) are evolutionarily conserved 
structurally similar to each other. UBQLN1 is approximately a 63 kDa protein and has 
3 main domains: ubiquitin-like domain (UBL) at the N-terminus, ubiquitin-associated 
domain (UBA) at the C-terminus and STI-1 chaperone-like regions in the middle (Fig. 
1A). UBQLN1 interacts with IGF1R and its UBA domain is required to stabilize IGF1R 




lung adenocarcinomas and loss of either UBQLN1 or UBQLN2 promotes epithelial to 
mesenchymal transition (EMT) in lung adenocarcinoma cell lines (Shah et al., 2015). 
UBQLN1 is known to regulate other cell surface receptors like Presenilins (Mah et al., 
2000), GABAA receptors (Saliba et al., 2008; Y. Zhang et al., 2015) and nicotinic 
acetylcholine receptors (Ficklin et al., 2005). Here, we demonstrate that UBQLN1 
interacts with IGF1R, IGF2R and INSR and is essential for the normal expression and 
activity of IGF1R in lung adenocarcinoma cells.  
IGF1R Structure and Trafficking: The IGF1R is synthesized as an immature 
pro-receptor monomer that undergoes maturation though proteolysis and glycosylation 
to form dimers. IGF1 receptors are present on the cell surface as preformed dimers 
unlike EGFR that form dimers upon ligand binding (Figure 3). The β subunit consists 
of 627 amino acids, has a small extracellular portion, transmembrane portion and the 
intracellular C-terminal. The juxtamembranous region in the β subunit hosts the NPXY 
motif and the catalytic region. The NPXY motif participates in the process of receptor 
internalization while the catalytic region is crucial for ATP binding. Tyrosine 1131, 1135 
and 1136 in the intracellular tyrosine kinase domains are critical for receptor 
autophosphorylation. The intracellular domains hold crucial signals that decide the fate 
of receptor trafficking once it is activated. For example, even though overall there is 
70% amino acid homology between IGF1R and Insulin receptor, there is only 44% 
homology in their C-terminus sequence which dictates the differences in downstream 
signaling pathways and functions between the 2 receptors. The NPXY motif 
recognizes the phosphotyrosine binding domains (PTB) of IRS proteins and SH2 
proteins (Figure 4). The IRS proteins (IRS 1-4) undergo full activation within 1-2 mins 
and Shc protein within 5-10 mins of ligand binding to IGF1R (Girnita et al., 2014). IRS 
proteins interact with IGF1R on the cell surface through their pleckstrin homology 
domains (PH) and PTB domains are present in their N-terminus. The C-terminus 
region of IRS proteins are variable and control the variety of interactions with other 




that have an SH 2 domain like PI3K, Grb2, SH-PTP2 (phosphatase), adaptor proteins 
like CRK, NCK1 which act as docking proteins for interaction of IGF1R with other 
proteins like β1 integrins on the cell surface.  Like IRS proteins, SHC proteins (SHC A-
D) also consist of a PTB domain at their N-terminal and a SH2 domain at their C-
terminal and interact with proteins in a similar fashion. These domains, their 
characteristics and the interactions they are capable of control further trafficking events 
of the activated receptor. Internalization of IGF1R is known to occur through clathrin 
mediated endocytosis (CME) and also through caveolin-mediated endocytosis at high 
levels of IGF1 (Goh & Sorkin, 2013). Internalized RTK’s in early endosomes proceed 
to late endosomes and continue to send signals through their C-terminus in the 
cytoplasm. In the late endosome, the RTK either gets recycled back to the plasma 
membrane through a recycling endosome or gets degraded via lysosomal or 
proteasomal pathways (Figure 5). Multi-protein complexes called Endosomal Sorting 
Complex Required for Transport (ESCRT) are critical for cellular transport of activated 
receptors (Goh & Sorkin, 2013). These processes occur by systematic co-operation of 
a variety of adaptor proteins and in absence of an interacting partner can potentially 
disturb trafficking and alter biological consequences. Ubiquitin interacting motif (UIM) 
containing adaptor proteins like Epsin, Eps15, Eps15R recognize ubiquitin on RTKs, 
bind to clathrin and AP2 simultaneously and are critical for clathrin mediated 
endocytosis (CME) of some RTKs like EGFR (Figure 6). The NPXY motif not only 
regulates internalization of IGF1R but also its downregulation. All RTKs possess a 
ubiquitin binding motif and ubiquitination has been well established as a crucial 
regulatory process of RTK trafficking. Ubiquitin is a small protein (7 kD) that is added 
to IGF1R in 3 consecutive steps via the E1, E2 and E3 ligases. The first two enzymes, 
E1 and E2 work to load the last enzyme E3 on to IGF1R to add ubiquitin molecules on 
the receptor. IGF1R is a known substrate of three E3 ligases:  Mdm2 (Girnita, Girnita, 
& Larsson, 2003)  Nedd4 (Vecchione, Marchese, Henry, Rotin, & Morrione, 2003) and 




before entering the endocytic vessels during internalization (Vecchione et al., 2003). 
Mdm2 poly-ubiquitinates IGF1R with K63-type chains and β-arrestins have been 
identified as crucial adaptor proteins to recruit Mdm2 to IGF1R (Girnita et al., 2005). 
Similarly, Grb10 is a key adaptor protein that recruits Nedd4 to IGF1R which multi 
mono-ubiquitnates the receptor (Vecchione et al., 2003). At higher doses of IGF1, c-
Cbl poly-ubiquitinates IGF1R with K48-type chains. Mdm2 recruitment favors 
stimulation of MAPK over PI3K pathways. Like IGF1R, EGFR is also poly-ubiquitinated 
with K63-type chains (Huang, Kirkpatrick, Jiang, Gygi, & Sorkin, 2006). K48 poly-
ubiquitination signals target substrates for proteasomal degradation while K63 mono- 
and poly-ubiquitination are recognized by other proteins through their ubiquitin binding 
domains (UBD) and activate enzyme cascades like kinases, phosphatases, 
phospholipases and so on that feed into and activate multiple downstream pathways 
like PI3K/AKT, RAS/MAPK, metabolic pathways and others (Adhikari & Chen, 2009; 
Varadan et al., 2004). Ubiquitination is a major molecular signal responsible for 
endocytic sorting such that ubiquitination of IGF1R is essential for its internalization 
while is not for other RTKs like EGFR and FGFR2. However, degradation of these 3 
RTK’s is highly dependent on their ubiquitin-conjugation (Haugsten, Malecki, 
Bjorklund, Olsnes, & Wesche, 2008; Huang et al., 2006; Mao et al., 2011). Previously, 
we have reported that UBQLN1 interacts with IGF1R and UBQLN1’s UBA domain is 
required to stabilize it. We have also published that UBQLN1 is lost and under-
expressed in 50% of lung adenocarcinomas and loss of either UBQLN1 or UBQLN2 
promotes epithelial to mesenchymal transition (EMT) in lung adenocarcinoma cell lines 
(Shah et al., 2015). Here, we demonstrate that UBQLN1 interacts with IGF1R, IGF2R 






Figure 14: IGF1R signaling pathways. Adapted from Girnita et 
al, 2014. Upon activation by ligand IGF1, there is 
phosphorylation of intracellular tyrosine kinase domains of 
IGF1R.  The activated receptor phosphorylates IRS and Shc 
proteins as its first substrates, which further activate other 
proteins like GRB2, SOS and so on. Broadly, IGF1R leads to 
activation of 2 major kinase cascades - RAS/MAPK and PI3/AKT 
pathways (Girnita et al., 2014) 
 
 
Figure 13: Schematic of structural domains of IGF1R 
Receptor tyrosine kinases have an extracellular domain that 
binds to and is activated by ligand, a transmembrane domain 
spanning across the plasma membrane and an intracellular 
domain bearing multiple tyrosine residues that undergo auto- 
and trans- phosphorylation. The above schematic is of the 
receptor tyrosine kinase IGF1R that is present on the plasma 
membrane as a preformed homodimer held together by disulfide 


















Figure 15: IGF-1R structure–function relationship. Adapted 
from(Girnita, Worrall, Takahashi, Seregard, & Girnita, 2014) This map 
depicts location of amino acid residues in IGF1R and their functions, their 
binding partners and posttranslational modifications (PTMs) at these 














Figure 16: Endocytic Trafficking of RTK 
Adapted from Goh & Sorkin (Goh & Sorkin, 2013). This figure 
shows 2 pathways of endocytosis of ligand bound RTK: clathrin 
mediated and calveolin mediated. The internalized receptor in 
clathrin-coated vesicles (CCV) is transported to the early 
endosome (EE) to the sorting endosome (SE) or the 
mutivescicular body (MVB) and from here either to the recycle 
endosome to be recycled back to the plasma membrane or 
degraded in the lysosomal endosome (LE). 
	
Figure 17: Schematic of clathrin-mediated endocytosis of 
EGFR. Adapted from Madshus et al (Madshus & Stang, 2009)  
Phosphorylated RTK and activates tyrosine kinases facilitating 
binding of an E3 ligase Cbl to the C-terminal of the RTK, or 
indirectly via an adaptor protein Grb2. Poly-Ub chains added by 
Cbl interact with Ub-interaction motifs (UIMs) of Epsin-1 and 
Eps15 which act in co-ordination with other proteins (not shown) 
and subsequently cause invagination of the plasma membrane 





UBQLN1 interacts with IGF1R, IGF2R, and INSR 
We recently demonstrated that UBQLN1 interacts with IGF1R and UBQLN1’s UBA 
domain is required to protect IGF1R from MG132 (proteasomal inhibitor) mediated 
degradation (Kurlawala et al., 2017). Fig.18A shows the schematic of UBQLN1. We 
confirmed endogenous interaction between UBQLN1 and  IGF1R by 
Immunoprecipitation/Western Blot (IP/WB) analysis (Fig. 18B,C). In addition to IGF1R, 
UBQLN1 also interacts with IGF2R and INSR. We used IGF1R as a model receptor for 
future experiments. To determine IGF1R and UBQLN1 co-localize in cells, FLAG-
UBQLN1 was overexpressed in HEK 293T cells followed by immunofluorescence (Fig. 
18D). After adjusting for image saturation by JACop plugin of ImageJ software analysis, 
33.5% of FLAG-UBQLN1 was determined to overlap with endogenous IGF1R, calculated 
by the Costes method and Mander’s correlation coefficients. These immunofluorescence 
data imply that a fraction of total UBQLN1 in cells associates with IGF1R and support our 
recently published findings that UBQLN1 is available for interaction with other proteins 




























Figure 18: UBQLN1 interacts with IGF1R: A) Schematic of structure of 
UBQLN1wt protein. N-terminal UBL (Ubiquitin-Like) domain, C-terminal UBA 
(Ubiquitin-Associated) domain and 4 STI-1 domains in between.  B) 
Immunoprecipitation (IP) of overexpressed FLAG-tagged UBQLN1 followed 
by mass spectrometry (MS) analysis to identify FLAG conjugated proteins. 
MIG is the empty vector used as a control for overexpression. IGF1R, IGF2R 
and INSR were some of the top interacting partners of UBQLN1. C) HEK-
293T cells were transfected with either control siRNA (siNT) or siRNA against 
UBQLN1 (siUBQLN1) to knock down UBQLN1 and empty vector (control) or 
FLAG-tagged UBQLN1 (FLAG-UBQLN1) to overexpress UBQLN1, followed 
by immunoprecipitation by UBQLN1 antibody and Western Blot analysis. 
Interaction was detected between endogenous UBQLN1 and IGF1R which 
was absent when UBQLN1 was absent (siUBQLN1) and slightly increased 
with UBQLN1 overexpression. (D) Confocal microscopy images of indirect 
immunofluorescence staining for FLAG-UBQLN1 (red) and IGF1R (green) in 
HeLa cells. Co-localization was determined for using JACop plugin of ImageJ 
software. Automatic threshold for images were determined by the Costes 
method and overlap coefficients (Mander’s Correlation Coefficients) were 
calculated. For the chosen field, 33.5% of FLAG-UBQLN1 overlaps with 





UBQLN1 interacts with pro-form, phosphorylated and non-phosphorylated forms of 
IGF1R  
Next, we mapped the domains of UBQLN1 required for interaction with IGF1R using a 
series of  domain deletion constructs previously described (Kurlawala et al., 2017). As we 
showed with another transmembrane protein BCLb (Kurlawala et al., 2017), we found that 
the STI1 and STI2 domains of UBQLN1 are crucial for interaction with IGF1R. We 
examined cellular distribution of these constructs (FLAG tagged UBQLN1WT, UBQLN1ΔUBL, 
UBQLN1ΔSTI-1 and UBQLN1ΔUBA) (Fig. 19A) in HEK 293T cells by immunofluorescence to 
confirm that overall distribution of UBQLN1 protein missing individual domains did not 
change  (Fig. 19A). All constructs of UBQLN1 showed uniform distribution in the cytoplasm 
and all were distinctly absent from nuclei and vacuoles. STI-1 and STI-2 domains are 
responsible for interaction with IGF1R (Fig. 19B). We conducted additional interaction 
studies with overexpressed UBQLN1 in serum-free conditions devoid of receptor ligands 
and stimulation with exogenous IGF1 (Fig. 19C). Interestingly, UBQLN1 interacts with 
phosphorylated IGF1R, detected when the receptor is stimulated with exogenous IGF1, 
and this interaction disappears when phosphorylation is inhibited by Linsitinib, a specific 
small molecule inhibitor of IGF1R activity. UBQLN1 also interacts with non-phosphorylated 
IGF1R as detected in cells devoid of receptor stimulation (serum-free media) as well as 
complete media, serum-free media supplemented with IGF1 and in the presence of 
Linsitinib. Additionally, UBQLN1 interacts with the larger, pro-form of IGF1R detected at 
135 kD (Fig. 19D). Based on our interaction data, we conclude that UBQLN1’s  association 
with IGF1R is independent of its phosphorylation status and it appears that UBQLN1 is 






Figure 19: UBQLN1 interacts with pro-form, phosphorylated and non-
phosphorylated forms of IGF1R  
(A) HEK 293T cells were transfected with FLAG-UBQLN1ΔUBL, FLAG-UBQLN1ΔSTI-
1 and FLAG-UBQLN1ΔUBA constructs followed by indirect immunofluorescence of 
FLAG-UBQLN1. UBQLN1WT is distributed in the cytoplasm of transfected cells and 
is absent from nuclei and vacuoles. UBQLN1ΔUBL, UBQLN1ΔSTI-1 and UBQLN1ΔUBA 







Figure 19: UBQLN1 interacts with pro-form, phosphorylated and non-
phosphorylated forms of IGF1R  
(B) HEK 293T cells were transfected with FLAG-tagged constructs of UBQLN1 
(in A) followed by co-immunoprecipitation and Western Blot analysis. STI-1 
and STI-2 domains of UBQLN1 are required for interaction with IGF1R. (C) 
HEK 293T cells were transfected with empty vector or FLAG-UBQLN1 and 
cells were cultured in complete media (COMPLETE) or serum-free media 
supplemented with IGF1 (SS, IGF1) or Linsitinib (SS, LINSITINIB), a small 
molecule inhibitor of IGF1R activity, followed by co-immunoprecipitation and 
Western Blot analysis. UBQLN1 interacts with phosphorylated and non-
phosphorylated IGF1R. (IGF1:50ng/ml, Linsitinib:1uM). (D) HEK 293T cells 
were transfected with empty vector or FLAG-UBQLN1 showed that FLAG-
UBQLN1 interacts with both immature pro-form of IGF1R at 130kD and 





UBQLN1 regulates expression and activity of IGF1R in lung adenocarcinoma cells. 
Following confirmation of interaction between UBQLN1 and IGF1R, we tested effects of 
loss of UBQLN1 on steady state expression of IGF1R in A549 cells, a non-small cell lung 
adenocarcinoma cell line. UBQLN1 protein expression was downregulated using two 
different siRNAs for UBQLN1 (U1 KD#1 and U1 KD#2). A549 cells were cultured in 2 
different conditions: serum-free media for 12 hours and serum-free media (12 hours) 
supplemented with IGF1 (6 hours). Cells were incubated with Cycloheximide for an hour 
before adding IGF1 to block de novo protein synthesis, to allow assessment of steady 
state expression of IGF1R. Post-stimulation, cells were harvested, lysed and analyzed by 
Western Blot for total and phosphorylated IGF1R expression levels. While total IGF1R 
expression was decreased in UBQLN1 deficient cells in both conditions (Fig. 20A), 
differences were more pronounced post-stimulation with IGF1. Phosphorylated IGF1R 
levels were undetectable in serum free media, however, post stimulation with IGF1, the 
ratio of phosphorylated to total IGF1R levels was greatly increased in siUBQLN1 cells (2.4 











Figure 20: UBQLN1 regulates expression and activity of IGF1R 
(A) Expression and activity of IGF1R were tested in A549 lung cancer cells 
following downregulation of UBQLN1 with two different siRNA (U1 KD#1 and 
U1 KD#2). Cells were serum starved (SS) overnight (12 hours), incubated 
with protein synthesis inhibitor Cycloheximide one hour prior to 
supplementing serum-free media with IGF1. 6 hours later, cells were 
harvested and lysed analyzed by Western Blot. UBQLN1 knock down cells 
showed decrease in total IGF1R expression compared to control in both 
conditions. Post-stimulation with IGF1, phosphorylated IGF1R levels were 
detected in both control and UBQLN1 deficient cells, however, the ratio of 
phosphorylated to total IGF1R levels was greatly increased in UBQLN1 
deficient cells (2.4 and 2.2 times compared to control) as seen in the 
densitometry graphs in (B). Data are normalized to non-targeting siRNA 





Loss of UBQLN1 results in decreased cell surface expression of IGF1R 
Following Western Blot data that showed decreased total IGF1R expression in 
cells, saturation binding assays were performed to test if the overall decrease in 
total IGF1R expression also reflected as a decrease in receptor number on the cell 
surface. Radioligand binding assays were performed utilizing radioactive ligand 
(I125-IGF1) to test for differences in the number of binding sites (number of cell 
surface receptors) in HPL1D cells between UBQLN1 deficient cells and control 
(Fig. 21). In these experiments, HPL1D cells were transfected with UBQLN1 siRNA 
(siU1) or control (siNT) and 48 hours post-transfection, cells were incubated with 
increasing concentrations of the radiolabeled ligand (I125-IGF1) with the intention 
to saturate the receptors. The purpose of performing saturation binding assays 
was to determine the differences in maximum binding capacity Bmax (number of cell 
surface receptors) between UBQLN1 deficient cells and control. Plotting saturation 
curves showed that although the amount of radioactive ligand used did not saturate 
the receptors. Overall, number of cell surface IGF1 receptors were lower in 
UBQLN1 deficient cells while the Kd i.e. affinity is almost the same. Data are 

















 siNT siUBQLN1 
Bmax 
16542cpm 23149cpm 
9600.47 x 10-15 mmoles 13,434.89 x 10-
15 
mmoles 
Receptors/cell 46.955 +/- 16.779 15.65 +/- 7.991 
Kd 0.061 +/- 0.0077 nmol/L 0.058 +/- 0.0035 nmol/L 
 
Figure 21: Loss of UBQLN1 results in decreased cell surface 
expression of IGF1R 
Specific Binding for I125-IGF1 for both control and UBQLN1 
deficient cells are graphed. The table represents the differences in 
Bmax, Kd and number of receptors in HPL1D cells that have loss 
of UBQLN1. Bmax values are representative of one experiment for 
graphing purposes but receptor number and Kd values are 
calculated as average +/- standard error of mean from 3 individual 
experiments.   Radioactivity was measured as counts per minute 
(CPM) in a Beckman gamma counter (efficiency=0.45). Specific 
activity of I125-IGF1 = 1870 Ci/mmol. (Experiment was performed 






Loss of UBQLN1 accelerates loss of IGF1R  
After confirming that UBQLN1 regulates protein expression and phosphorylation activity 
of IGF1R at 6 hours post-stimulation with IGF1 (Fig. 21A), we asked whether loss of 
UBQLN1 altered recycling of IGF1R. Therefore, we examined cells at shorter and longer 
time points after IGF1 stimulation. A549 cells with stable expression of shRNA against 
UBQLN1 and control were treated with Cycloheximide, an inhibitor of de novo protein 
synthesis and tracked the expression and activity of IGF1R after IGF1 stimulation. We 
examined shorter time points, at intervals of 30 minutes from 0 to 180 minutes (Fig. 22A) 
and longer time points up to 24 hours (Fig. 22B) after adding exogenous IGF1.  Overall, 
the pattern of phosphorylation of IGF1R between UBQLN1 deficient cells and control cells 
were almost identical. Based on our time points, IGF1R achieved peak phosphorylation 
by 30 minutes. While control cells maintained steady levels of total IGF1R throughout 180 
mins of stimulation, its expression started to decline in UBQLN1 deficient cells by 90 
minutes. This effect on IGF1R loss in UBQLN1 deficient cells was seen more clearly when 
we tracked receptor expression for 24 hours following IGF1 stimulation. While expression 
of IGF1R declined and begun to rise gradually in control cells, UBQLN1 deficient cells lost 
almost all IGF1R by 24 hours. Cycloheximide causes arrest of translational machinery 
thus preventing all new protein synthesis resulting from transcription. Therefore, it is likely 
that the increase in IGF1R expression observed in control cells is not due to increase in 
transcription but due to stimulation of Endoplasmic Reticulum (ER) and Golgi processing 
of pre-formed, already translated monomers to its mature dimerized form. UBQLN1 plays 
a role in stabilizing and assembling newly translated GABAA receptors in the ER (Saliba 
et al., 2008) and we hypothesize that it may do the same with IGF1R. Thus, it is possible 









Figure 22:  Loss of UBQLN1 accelerates loss of IGF1R 
A549 cells expressing shRNA against UBQLN1 were incubated with 
Cycloheximide (20uM), an inhibitor of de novo protein synthesis to study loss of 
IGF1R expression in UBQLN1 deficient cells, post-stimulation with IGF1. Cells 
were harvested at the indicated time points and Western Blot analysis for 
phosphorylated and total receptor levels were performed and graphed. (A) 
Post-stimulation, cells were harvested at intervals of 30 mins from 0 to 180 
minutes Western Blot analysis were performed with the indicated antibodies. 






Loss of UBQLN1 inhibits recycling of IGF1R 
Since UBQLN1 deficient cells have accelerated loss of IGF1R, we studied whether 
UBQLN1 altered recycling and degradation of the receptor. We used Monensin, an 
ionophore that traps the internalized receptor within early endosomes and prevents their 
recycling back to the cell surface. With vehicle treatment (Fig. 23A), UBQLN1 deficient 
cells have faster loss of IGF1R when compared to control. With Monensin treatment (Fig. 
23B), expression of total IGF1R was parallel between control and UBQLN1 deficient cells.  
Interestingly, this pattern of IGF1R expression in Monensin treated cells imitated the 
pattern of IGF1R expression in vehicle treated UBQLN1 deficient cells. Based on these 
data, we conclude that loss of UBQLN1 has the same effect on IGF1R expression as 
Monensin does. This implies that loss of UBQLN1 may block recycling of IGF1R and cause 












Figure 23:  Loss of UBQLN1 inhibits recycling of IGF1R 
A549 cells expressing shRNA against UBQLN1 were serum starved for 12 hours, 
incubated with Vehicle (A) or Monensin (B), inhibitor of early endosomes for an 
hour prior to stimulation with IGF1 and harvested post-stimulation at the indicated 
time points. Western Blot analysis for phosphorylated and total receptor levels 
were performed and graphed in both control and UBQLN1 deficient cells. 
Densitometry of Western Blot images were performed using ImageJ and P-
IGF1R and T-IGF1R expression were normalized to Actin expression in control 
cells for each treatment. (Experiment was performed twice for Monensin but once 





UBQLN1 does not play a role in IGF1R turnover through the proteasome 
We conducted a similar experiment by inhibiting the proteasome with Bortezomib. As seen 
in vehicle (Fig. 24A), UBQLN1 deficient cells have lower expression of IGF1R, while 
expression in control cells steadily increases. Inhibiting proteasomal degradation with 
Boretzomib (Fig. 24B) prolonged the phosphorylation of IGF1R compared to vehicles and 
caused an initial accumulation of total IGF1R in UBQLN1 deficient cells which is eventually 
lost probably due to recruitment of other degradation pathways like the lysosome. There 
are no gross differences between vehicle and Bortezomib treatment in both control and 
UBQLN1 deficient cells. Based on these data, we conclude that UBQLN1 may not play a 









Figure 24:  UBQLN1 does not play a role in IGF1R turnover through the 
proteasome 
A549 cells expressing shRNA against UBQLN1 were serum starved for 12 hours, 
incubated with Vehicle (A) or Bortezomib (B), a proteasomal inhibitor for an hour 
prior to stimulation with IGF1 and harvested post-stimulation at the indicated time 
points. Western Blot analysis for phosphorylated and total receptor levels were 
performed and graphed. Densitometry of Western Blot images were performed 
using ImageJ and P-IGF1R and T-IGF1R expression was normalized to Actin 
expression in control. Experiment was performed twice for Bortezomib but once for 







Loss of UBQLN1 may direct IGF1R towards higher density compartments  
Next, we examined whether loss of UBQLN1 altered intracellular transport of IGF1R. To 
study gross differences in trafficking and organelle distribution of IGF1R in UBQLN1 
deficient cells, A549 cells (control and shRNA against UBQLN1) were serum starved for 
12 hours (Fig. 25A,C) and stimulated with IGF1 for 1 hour (Fig. 25B,D), harvested and 
cell lysates were loaded onto a Percoll density gradient. Every other fraction was resolved 
via SDS-PAGE and immunoblotted for markers of various organelles (EEA1=early 
endosomes, TfnR=plasma membrane/recycling/early endosomes).  Note that an Rf value 
of 1.0 represents the top of the gradient tube, while an Rf value of 0 represents the bottom 
of the gradient. Therefore, higher density organelle associated markers like LAMP1 for 
late endosomes are detected in the higher gradients towards Rf=1.0 and lower density 
gradient associated markers like EEA1 for early endosomes are detected towards Rf=0. 
Here, we probed for IGF1R, TfnR and EEA1. In UBQLN1 deficient cells, distribution of 
IGF1R and TfnR was slightly shifted towards higher density gradients like the lysosome 
compared to control. This indicates that loss of UBQLN1 may be altering trafficking of 






















Figure 25: Loss of UBQLN1 may direct IGF1R towards higher density 
compartments 
A549 cells (control and shRNA against UBQLN1) were serum starved (12 hours) 
(A) and stimulated with IGF1 for 1 hour (B), harvested and cell lysates were loaded 
onto a Percoll density gradient. Every other fraction was resolved via SDS-PAGE 
and immunoblotted IGF1R and for markers of various organelles (TfnR=transferrin 
receptor, plasma membrane/recycling/early endosomes, EEA1=early endosome 
antigen 1, early endosomes).  Note that an Rf value of 1.0 represents markers 
associated with higher density gradients, while an Rf value of 0 represents lower 
density gradients). (Experiment was performed thrice. Data are representative of 

















Figure 25: Loss of UBQLN1 may direct IGF1R towards higher density 
compartments 
These graphs represent densitometry quantifications of Western Blot analysis n 
both serum starved (C) and IGF1 stimulated (D) conditions, there is a slight 
leftward shift in distribution of IGF1R and TfnR in UBQLN1 deficient cells 
compared to control indicating that loss of UBQLN1 may be directing internalized 
cell surface receptors (IGF1R and TfnR) towards higher density compartments 





UBQLN1 deficient A549 cells have increased survival in serum-free conditions 
A549 cells expressing stable shRNA against UBQLN1 (U1 KD#1, U1 KD#2, and control) 
were cultured in conditions of serum-free media and serum-free media supplemented with 
IGF1 for 4 days (Fig. 26). Alamar Blue readings were recorded every 24 hours. UBQLN1 
deficient cells gradually begun to outsurvive control cells when cultured in serum-free 
media by Day 2 (Fig. 26A). Supplementing serum-free media with IGF1 (Fig. 26B) 
corresponded with a slight survival advantage in UBQLN1 deficient cells compared to 
control. Based on these data, we conclude that loss of UBQLN1 inherently confered a 
growth and survival advantage to A549 cells when cultured in serum-free media, and this 
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Figure 26: UBQLN1 deficient A549 cells have increased survival in serum-
free conditions 
A549 cells expressing stable shRNA against UBQLN1 (U1 KD#1, U1 KD#2, and 
control) were cultured in conditions of serum-free media and serum-free media 
supplemented with IGF1 for 4 days. Alamar Blue readings were recorded every 
24 hours. Day 2 onwards, UBQLN1 deficient cells gradually begun to outsurvive 
control cells when cultured in serum-free media (A) and supplementing serum-
free media with IGF1 (B) enhanced survival of these cells. Data are represented 
as mean±SEM from 2 independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 





Activation of IGF1 pathway in UBQLN1 deficient A549 cells increases their 
migration potential 3-fold 
We have previously published that lung adenocarcinoma cells (A549 and H358) that have 
loss of UBQLN1 are more migratory and invasive (Shah et al., 2015). Here, we 
investigated whether UBQLN1 deficient A549 cells migrate more upon stimulation of IGF 
pathway. In a transwell cell migration assay, cells were cultured in the top chamber in one 
of 3 conditions – serum-free media, serum-free media supplemented with IGF1 and 
serum-free media supplemented with IGF1 and Linsitinib, a small molecule inhibitor of 
IGF1R activity. Media supplemented with 10% FBS was used as chemo-attractant in the 
bottom chamber. At the end of 24 hours, pictures of migrated cells were captured (Fig. 
27A) and number of migrated cells were quantified by ImageJ software (Fig. 27B). 
UBQLN1 deficient cells are inherently more migratory compared to control as observed in 
serum-free conditions. When stimulated with IGF1, there was a 3-fold increase in 
migration in UBQLN1 deficient cells compared to serum-free conditions (p<0.01) whereas 
IGF1 stimulation did not significantly increase migration in control cells. Migration returned 
to baseline by Linsitinib in all cells and it appears that UBQLN1 deficient cells are more 
sensitive to inhibition than control.  Based on these data, we conlude that activation of 
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Figure 27:  Activation of IGF1 pathway in UBQN1 deficient A549 cells 
increases their migration potential 3-fold 
A549 cells expressing stable shRNA against UBQLN1 (U1 KD#1, U1 KD#2, 
and control) (Fig. 29E) were seeded in a transwell setup to assess cell 
migration in response to IGF1 stimulation. Cells were cultured in the top 
chamber in one of 3 conditions – serum-free media, serum-free media 
supplemented with IGF1 and serum-free media supplemented with Linsitinib, 
a small molecule inhibitor of IGF1R activity. Media supplemented with 10% 
FBS was used as chemo-attractant in the bottom chamber. At the end of 24 
hours, cells were fixed and HEMA3 stained (A). Number of migrated cells were 
quantified by ImageJ software and analyzed by ANOVA (B). UBQLN1 
deficient cells are inherently more migratory (3-4 times compared to control) 
as observed in serum-free conditions. When UBQLN1 deficient cells were 
stimulated with IGF1, there was a 3-fold increase in migration compared to 
control cells. Linsitinib blocked cell migration and brought it back to control 
cells’ baseline levels. Data are represented as mean±SEM from three 





STI-1/2 domains of UBQLN1 interact with Insulin receptor (INSR) and loss of 
UBQLN1 regulates expression of INSR and IGF2R post-stimulation with IGF1. 
HEK293T cells were transfected domain deletion constructs of UBQLN1 followed by 
immunoprecipitation by FLAG antibody and probed for INSR. As with IGF1R, UBQLN1 
interacts with INSR and we mapped this interaction to the STI-1/2 domains (Fig. 28). We 
examined whether UBQLN1 regulates expression of INSR as it does with IGF1R. A549 
cells with stable expression of shRNA against UBQLN1 and control were cultured in 4 
different conditions (Fig 29A): complete media, serum-free media for 12 hours and serum-
free media (12 hours) supplemented with IGF1 (6 hours) and serum-free media (12 hours) 
supplemented with Linsitinib (1uM), an IGF1R activity inhibitor. Cells were incubated with 
Cycloheximide an hour before adding IGF1 to block de novo protein synthesis, which 
enabled assessment of steady state expression of INSR. Post-stimulation, cells were 
harvested, lysed and analyzed by Western Blot. The antibody used to detect phospho-
IGF1R recognizes auto-phosphorylation site Tyr1135 on IGF1R and cross-reacts with 
Tyr1150 on INSR, which shows increased phosphorylation in UBQLN1 deficient cells. 
INSR expression in UBQLN1 knock down cells was notably decreased upon serum-
starvation and stimulation with IGF1. Loss of UBQLN1 also caused loss of IGF2R upon 
ligand stimulation in A549 cells (Fig. 29B). Based on these data, we conclude that 
UBQLN1 interacts with INSR and regulates expression of INSR and IGF2R post-
stimulation with IGF1. Additionally, AKT, a critical regular of survival and apoptosis is 
activated (p-AKT) in A549 cells that have loss of UBQLN1 and more so when the IGF 
pathway is stimulated with exogenous ligand. Therefore, next we tested for survival of 



















    
 
	
Figure 28: STI-1/2 domains of UBQLN1 interact with Insulin receptor 
(INSR)  
HEK 293T cells were transfected with FLAG-tagged constructs of UBQLN1 
followed by co-immunoprecipitation by FLAG antibody and Western Blot 
analysis. STI-1 and STI-2 domains of UBQLN1 are required for interaction 
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Figure 29: Loss of UBQLN1 regulates expression of INSR and IGF2R post-
stimulation with IGF1. 
(A) Expression and activity of INSR were tested in A549 lung cancer cells (control and 
shRNA against UBQLN1: U1 KD#1 and U1 KD#2). Cells were serum starved (SS) for 12 
hours, or supplemented with IGF1 (6 hours) or Linsitinib, a small molecule inhibitor of 
IGF1R activity. INSR expression was decreased in UBQLN1 deficient cells only in serum 
starved and IGF1-stimulated conditions. Additionally, UBQLN1 deficient cells showed 
increased basal expression of P-AKT which was enhanced by IGF1 stimulation, while T-
AKT levels remained constant across all conditions for both control and UBQLN1 deficient 
A549 cells. (B) Expression and activity of IGF2R were tested in the above cells. Cells 
were serum starved (SS) for 12 hours and supplemented with IGF as in D. Expression of 





UBQLN1 deficient A549 cells have decreased autocrine ligand production 
compared to control  
We hypothesized that UBQLN1 deficient A549 cells may be responsible for autocrine 
production of its ligands (IGF1, IGF2, Insulin), which can consequently lead to activation 
of AKT and therefore survival and anti-apoptotic pathways. To investigate this, mRNA 
expression of IGF1 and IGF2 were tested in these cells cultured in complete media and 
serum-free conditions (72 hours). Contrary to our hypothesis, IGF1 expression was 
significantly lower in UBQLN1 deficient cells in both conditions (Fig. 30A,B). IGF2 
expression was unchanged between control and UBQLN1 deficient cells in complete 
media (Fig. 30C,D). Although not statistically significant, when serum starved, production 
of IGF2 seemed to be decreasing in UBQLN1 knock down cells compared to control. 
Based on these data, we conclude that survival advantage conferred to cells upon 
UBQLN1 knock down may not be due to autocrine ligand production but mediated through 
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Figure 30: UBQLN1 deficient A549 cells have decreased autocrine ligand 
production compared to control 
A549 cells expressing stable shRNA against UBQLN1 (U1 KD#1, U1 KD#2 and 
control) were cultured in conditions of complete media or serum-free media for 72 
hours and real time analysis of IGF1 and IGF2 mRNA were performed. UBQLN1 
deficient A549 cells showed significantly decreased production of IGF1 compared to 
control when these cells were cultured in both, complete (A) (p<0.05) and serum-free 
media (B) (p<0.001). Production of IGF2 was unchanged between these cells in 
complete media (C) but showed a decreasing trend in UBQLN1 deficient cells upon 
serum starvation (D). These data were not statistically significant. (Data are averaged 









UBQLN1 does not stably associate with these markers of endocytic trafficking: 
GRB10, EEA1, RAB7, LAMP1, Caveolin1 
Loss of UBQLN1 altered lysosomal trafficking of IGF1R and Percoll density gradient 
fractionation showed that there may be a slight shift of IGF1R toards higher density 
gradients like the lysosomes, we investigated whether UBQLN1 interacts with IGF1R as 
it is internalized and proceeds through the endocytic pathway and possibly alters its 
trafficking (Fig. 31). We simply tested UBQLN1’s interaction with a few known markers on 
endocytosis. FLAG-UBQLN1WT, UBQLN1112X and UBQLN1DUBA were overexpressed in 
cells followed by Immunoprecipitation pull down with FLAG antibody and probed for the 
respective proteins. We did not detect an interaction for any of these markers. However, 

























Figure 31: UBQLN1 does not stably associate with these markers of 
endocytic trafficking: GRB10, EEA1, RAB7, LAMP1, Caveolin1 
HEK 293T cells were transfected with FLAG-UBQLN1WT, UBQLN1112X and 
UBQLN1DUBA followed by immunoprecipitation by FLAG antibody and Western Blot 
analysis. Interaction was tested for the markers of the endocytic pathway as shown 
above in the table. CD47 or Integrin Associated Protein (IAP) was used as a 
positive control, as a known interacting partner of UBQLN1. UBQLN1 did not 
interact with these proteins tested. However, a faint interaction is detected for 





Combined loss of UBQLN1 and PTP1B has a synergistic effect on activation of 
kinase domain of IGF1R 
Since UBQLN1 deficient cells have an increased ratio of active:total IGF receptors, we 
investigated whether this effect was exclusive of action of phosphatases for IGF1R.  H358 
lung adenocarcinoma cells were transfected with siRNA for UBQLN1 and PTP1B, a known 
phosphatase of IGF1R. Cells were cultured in complete media and 48 hours post-
transfection, Western Blot analysis were performed and probed for auto-phosphorylation 
and kinase activation sites of IGF1R by specific antibodies as shown (Fig. 32). Loss of 
UBQLN1 showed slight increase in auto-phosphorylation of IGF1R compared to control. 
Loss of PTP1B did not show more auto-phosphorylation compared to control. Combined 
effect of loss of both, showed no additional increases in auto-phosphorylation of IGF1R.  
However, combined loss of UBQLN1 and PTP1B have a synergistic effect on activation 




















Figure 32: Combined loss of UBQLN1 and PTP1B has a synergistic 
effect on activation of kinase domain of IGF1R 
H358 lung adenocarcinoma cells were transfected with siRNA for 
UBQLN1 and PTP1B. Cells were cultured in complete media and 48 
hours post-transfection, Western Blot analysis were performed and 
probed for auto-phosphorylation and kinase activation sites of IGF1R by 
specific antibodies as shown. Loss of UBQLN1 and combined loss of 
UBQLN1 and PTP1B show a small increase in autophosphorylation of 
IGF1R. However, there is a synergistic effect of combined loss of both 





UBQLN1 and UBQLN2 interact with Epidermal Growth Factor Receptor (EGFR) 
Since UBQLN1 interacts with and reguates IGF receptor tyrosine kinases, we examined 
whether UBQLN also interacts with other receptor tyrsoine kinases like EGFR. FLAG-
UBQLN1 and FLAG-UBQLN2 were overexpressed in HEK293T cells followed by 
immunoprecipitation by FLAG antibody. Both, UBQLN1 and UBQLN2 interact  with EGFR 











Figure 33: UBQLN1 and UBQLN2 interact with EGFR 
HEK293T cells were transfected with empty vector (EV) or FLAG-UBQLN1 or FLAG-
UBQLN2. 48 hours post transfections, cells were lysed followed by 
immunoprecipitation by FLAG antibody and probed for EGFR by Western Blot analysis. 




UBQLN1 regulates EGFR expression in K-RAS mutant A549 cells but not in EGFR 
mutant H1650 cells 
We investigated whether UBQLN1 can universally regulate EGFR expression and 
therefore tested for effects of loss of UBQLN1 in k-ras mutant A549 (Fig. 34A) and EGFR 
mutant H1650 (Fig. 34B) lung adenocarcinoma cells. These cells were transfected with 
siRNA for UBQLN1. Cells were serum starved (SS) for 12 hours, or supplemented with 
EGF (50ng/ml for 1 hour) or Erlotinib (50nM), a small molecule inhibitor of EGFR kinase 
domain. A549 cells showed increased phosphorylated EGFR levels in UBQLN1 deficient 
cells and decreased total EGFR expression was in UBQLN1 deficient cells only in EGF-
stimulated condition. These data are similar to UBQLN1’s regulation of IGF1R. However, 
H1650 cells did not show a similar effect. Although, phosphorylated EGFR expression was 
increased in UBQLN1 deficient cells in complete media, this effect was very slight and not 
accompanied with decrease in but total receptor expression as seen in A549 cells. Based 
on these data, we conclude that UBQLN1 regulates wild type EGFR but not mutant EGFR 
(E746-750Adel). A549 cells show increased basal phosphorylation of AKT in UBQLN1 
deficient cells in all conditions tested as also seen in Fig. 29A. However, basal p-AKT 
expression completely disappeared upon inhibition of EGFR activity but not with inhibition 
of IGF1R activity. This implies that between these 2 receptor pathways, stimulation of 
EGFR has a dominant effect on AKT activation (phosphorylation of Ser 473) and may be 
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Figure 34: UBQLN1 regulates EGFR expression in K-RAS mutant A549 cells 
but not in EGFR mutant H1650 cells 
A549 and H1650 lung adenocarcinoma cells were transfected with siRNA for 
UBQLN1. Cells were serum starved (SS) for 12 hours, or supplemented with EGF 
(50ng/ml, 1 hour) or Erlotinib (50nM), a small molecule inhibitor of EGFR kinase 
domain. (A) A549 cells showed increased phosphorylated EGFR levels in UBQLN1 
deficient cells. Total EGFR expression was decreased in UBQLN1 deficient cells 
only in EGF-stimulated condition. (B) Phosphorylated EGFR expression was 
increased in UBQLN1 deficient H1650 cells in complete media, but total receptor 





EGF-dose dependent regulation of EGFR by UBQLN1 
We observed that loss of UBQLN1 accelerates loss of EGFR post-stimulation with ligand, 
as seen with IGF1R. Here we tested loss in expression of EGFR with 2 different doses of 
EGF in A549 cells (Fig. 35). Cells were serum starved (SS) for 12 hours and supplemented 
with EGF (1 hour) with 2 different doses: 10ng/ml (Fig. 35A) and 100ng/ml (Fig. 35B). 
Overall, phosphorylated EGFR expression was higher when cells were stimulated with 
100ng/ml EGF. For both ligand concentrations, phosphorylated EGFR expression was 
higher in UBQLN1 deficient cells. For both ligand concentrations, EGFR expression was 
decreased faster in UBQLN1 deficient cells and more pronounced with higher dose of 
ligand. Based on these data, we conclude that UBQLN1 may regulate EGFR in a EGF-
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Figure 35:  EGF-dose dependent regulation of EGFR by UBQLN1 
A549 were transfected with siRNA for UBQLN1. Cells were serum starved (SS) for 
12 hours and supplemented with EGF (1 hour) with 2 different doses: 10ng/ml (A) 
and 100ng/ml (B). Overall, phosphorylated EGFR expression was higher in UBQLN1 
deficient cells for both ligand doses. Total EGFR expression decreased with receptor 







 Role of UBQLN proteins is slowly emerging in the field of cancer. Recently, it was 
reported that increased UBQLN2 expression within osteosarcoma cells enhances tumor 
progression in patients. UBQLN2 expression in urine was also proposed to be used as a 
biomarker to diagnose, stage and grade urothelial cancer (Shimada et al., 2016). Our lab 
has published that UBQLN1 is lost and under-expressed in approximately fifty percent of 
non-small cell lung cancers (Shah et al., 2015). Cells that have loss of UBQLN1 adopt a 
more epithelial-to-mesenchymal (EMT) phenotype and are more and migratory and 
invasive (Shah et al., 2015). In this manuscript, we determined the role of UBQLN1 in 
regulation of IGF1R, a receptor tyrosine kinase overexpressed in lung cancer.  
 We have previously determined that fate of substrates UBQLN1 associates with is 
interaction domain specific. Transmembrane proteins like BCLb, ESYT2, IGF1R (Fig. 19), 
INSR (Fig. 29) interact with UBQLN1 through its STI-1 and STI-2 domains and are 
stabilized as a result of this interaction. UBQLN1 does not alter stability of substrates 
involved in proteasomal machinery like BAG6 and PSMD4 that associate through its UBL 
domain (Kurlawala et al., 2017). UBQLN1’s interaction with IGF1R is unusual because 
unlike other regulators, this interaction is not dependent on phosphorylation of IGF1R. 
UBQLN1 interacts with all forms of IGF1R - non-processed immature form (pro-IGF1R) 
,phosphorylated form and non-phosphorylated form (Fig. 19). It appears that UBQLN1 is 
recruited to IGF1R from the time of its synthesis and remains bound to it during trafficking. 
Known binding partners of IGF1R like IRS (L. M. Wang et al., 1993) , Shc (Wills & Jones, 
2012), Grb2 , Grb10 (Dufresne & Smith, 2005; Langlais et al., 2004; Mori, Giovannone, & 
Smith, 2005; Ramos, Langlais, Hu, Dong, & Liu, 2006; Stein, Gustafson, & Hubbard, 2001) 
are recruited to IGF1R only when the receptor is stimulated by ligand, auto-




IRS and Shc proteins are one of the first to bind to IGF1R which allows subsequent 
recruitment of more molecules in turn stimulating other signaling pathways. GRB10 (direct 
recruitment) and GIGYF2 (recruitment through GRB10) bind to IGF1R and have been 
identified as negative regulators of IGF1R phosphorylation (Giovannone et al., 2009). We 
found that UBQLN1 is a positive regulator of total-IGF1R expression. Loss of UBQLN1 
causes accelerated loss of IGF1R and overexpression of UBQLN1 stabilizes it (Kurlawala 
et al., 2017).  
 Role of UBQLN1 has been studied in regulation of  cell surface receptors like 
GABAA receptors (Saliba et al., 2008), Presenilins (Mah et al., 2000; Massey et al., 2004; 
Massey et al., 2005), GPCR’s (N'Diaye et al., 2008) and nicotinic acetylcholine receptors 
(Ficklin et al., 2005) and others. Regulation of IGF1R by UBQLN1 is similar to its regulation 
of GABAA receptors which has been studied in detail (Bedford et al., 2001; Saliba et al., 
2008). UBQLN1 interacts with GABAA receptors through its UBA domain. Loss of 
interaction led to decrease in receptor numbers, without an effect on rate of internalization 
or endocytosis. Similarly, UBQLN1 stabilizes full length Presinilins and prevents its 
fragmentation within the gamma secretase complex embedded in the plasma membrane 
(Massey et al., 2005). In A549 lung cancer cells, loss of UBQLN1 causes accelerated loss 
of IGF1R without gross changes in trafficking or phosphorylation activity. We have a few 
theories that may possibly explain this phenomena. Loss of UBQLN1 causes decreased 
mRNA expression of IGF1R. When new protein synthesis is blocked by Cycloheximide, 
loss of UBQLN1 can lead to faster loss of the relatively smaller existing pool of receptors. 
We have not determined whether UBQLN1 has a direct or indirect effect on gene 
transcription of IGF1R but based on our immunofluorescence data in variety of cell types 
(HEK 293T, HeLa, A549, H358 and HPL1D, Fig. 2, 19, 20), we have not detected nuclear 
presence of UBQLN1 thus far. Another reason for decreased transcription of IGF1R could 




deficient cells leading to suppression of signal for new receptor synthesis. Once 
translated, multi-subunit proteins like IGF1R and GABAA receptors are assembled and 
processed in the Endoplasmic Reticulum and Golgi before delivery and insertion to 
designated organelles. However, the process of assembly is inefficient and only 25% of 
translated proteins are assembled into mature forms. Overexpression of UBQLN1 caused 
a ~30% increase in Endo H sensitive GABAA receptors in the ER (Saliba et al., 2008).  
UBQLN1 interacts with the higher molecular weight (~135kD), pro-form of IGF1R and 
therefore maybe involved in assembly of IGF1R in the ER. Additionally, transport of these 
receptors to the cell surface takes about 4-6 hours. It is yet to be investigated how long 
after loss of interaction between UBQLN1 and IGF1R, does IGF1R expression begin to 
decrease. If the decrease in expression occurs within a matter of minutes after loss of 
interaction, it would indicate a stability/degradation based mechanism. However, if it takes 
hours, it would solidify UBQLN1’s role in assembly in the ER of IGF1R other 
transmembrane proteins like INSR, BCLb, ESYT2, OMP25, and so on.  
 UBQLN1 also interacts with Insulin receptor and loss of UBQLN1 regulates INSR 
expression when A549 cells are serum starved and activated by IGF1 (Fig. 20, 29). 
 Despite having decreased total receptor levels in UBQLN1 deficient cells, the ratio 
of active to inactive IGF1R was at least 2 times higher (Fig. 20) and combined loss of 
UBQLN1 and PTP1B caused a synergistic increase in phosphorylation of the kinase 
domain of IGF1R (Fig. 32). This may indicate that normal dephosphorylation of IGF1R 
may be delayed in absence of UBQLN1. PTP1B and SHP2 are known phosphatases that 
negatively regulate IGF1R phosphorylation in a ligand dependent manner (Buckley, 
Cheng, Kiely, Tremblay, & O'Connor, 2002). Phosphatases are recruited to the plasma 
membrane via adaptor proteins like SHPS2. It is known that IntegrinαVβ3 acts via SHP2 to 
dephosphorylate IGF1R (Rocchi, Tartare-Deckert, Sawka-Verhelle, Gamha, & van 




receptor for normal dephosphorylation directly or through participation in a multi-protein 
complex involving Integrins and other cell surface proteins that help recruit phosphatases 
to IGF1R to enable normal dephosphorylation. 
 One of UBQLN1’s primary functions is in protein quality control and 
depending on type of substrate either facilitates substrate degradation or 
stabilization. We have previously shown that transmembrane proteins like BCLb, 
ESYT2 and IGF1R are stabilized by interaction with UBQLN1 and its UBA domain 
protects from MG132 (proteasomal inhibitor) mediated degradation in HEK 293T 
cells. Here, we investigated in A549 lung cancer cells whether UBQLN1 plays a 
role in normal turnover of IGF1R. IGF1R is degraded via both lysosomal and 
proteasomal pathways. Therefore, we blocked both pathways individually with 
inhibitors to determine role of UBQLN1 in degradation of IGF1R. IGF1R recycling 
is prevented upon loss of UBQLN1 as the same effect is seen with Monensin (Fig. 
23) whereas blocking the proteasome did not seem to have a profound effect (Fig. 
24). Additionally, IGF1R was detected to be slightly shifted towards higher density 
compartments (ex. Lysosomes) upon loss on UBQLN1 (Fig. 25). Taken together, 
we conclude that UBQLN1 plays a role in lysosomal turnover of IGF1R. 
We then studied the biological relevance of UBQLN1’s association with IGF1R in 
context of cancer progression. We determined that UBQLN1 deficient A549 cells showed 
improved survival when serum starved (Fig. 26). This phenomena may be at least partially 
attributable to higher basal levels of active AKT protein in UBQLN1 deficient cells (Fig. 
29). Stimulation of the IGF pathway corresponded with an enhanced survival advantage 
(Fig. 26), possibly due to additional activation of AKT, a key central molecule activated 




promotes survival for example directly inactivating pro-apoptotic Bad, inactivating 
Caspase 9 (Datta et al., 1997), increasing expression of anti-apoptotic NFKB which then 
downregulates p53 (Jeong, Pise-Masison, Radonovich, Park, & Brady, 2005).  
 We have previously shown that lung adenocarcinoma cells that have loss of 
UBQLN1 adopt a more Epithelial-to-Mesenchymal Transition (EMT) like phenotype and 
are more migratory (Shah et al., 2015). Here, we found that stimulating UBQN1 deficient 
A549 cells with IGF1 increased their migratory potential 3-fold (Fig. 27). As UBQLN1 
interacts with several plasma membrane proteins like IGF1R, INSR, IAP, it is worth testing 
whether UBQLN1 participates in a multi-protein complex with these receptors at the 
plasma membrane such that loss of UBQLN1 facilitates increased ECM-cell 
communication promoting migration. The IGF pathway is known to promote cell migration 
in cancer cells through multiple pathways. It can cause disassembly of adherens junctions 
and redistribution of movement fibers promoting motility (Cox et al., 2015). In 
communication with the microenvironment, IGF1R signaling can induce expression of 
proteases like cathepsin D (F. Wang, Duan, Chirgwin, & Safe, 2000), matrix 
metalloproteinases (Yoon & Hurta, 2001; D. Zhang & Brodt, 2003) and urokinase 
plasminogen activator (Dunn, Torres, Oh, Cykert, & Barrett, 2001), promoting 
disintegration of basement membranes to facilitate cell migration. These proteases can 
also bind and cleave IGFBP3, which can release bound IGF1 for further stimulation 
(Cohen et al., 1992). Integrin activation from the extracellular matrix can also regulate 
IGF1R signaling to promote migration (Clemmons & Maile, 2003).  
 UBQLN1 interacts with receptor tyrosine kinases outside of the IGF pathway, such 
as the Epidermal Growth Factor Receptor, which is also mutated and overexpressed in a 
variety of cancers. We demonstrated that UBQLN1 and UBQLN2 interact with EGFR. For 
the two doses of EGF stimulation we tested (10ng/ml and 100ng/ml) UBQLN1 regulates 




 In conclusion, the IGF1 pathway axis has been a major target of research for 
chemotherapy. However, drugs that seem effective in in vitro, in vivo, and in early phase 
trials fail to show overall clinical benefit. The IGF pathway is complicated with presence of 
different receptor types including hybridization between receptors, multiple ligands, 
autocrine and paracrine stimulation, extensive influence of extracellular matrix signals, 
and compensatory signaling via other growth factor receptors. Additionally, intracellular 
IGF1R activity does not always correlate with its cell surface expression. We have also 
observed that IGF1R expression varies with cell confluence in vitro (data not shown). All 
these factors make it challenging to predict response to therapy thus highlighting the role 
of defining better biomarker profiles for choosing patients that will benefit from anti-IGF1R 
therapy. Therefore, it is essential to study cellular and extracellular factors that regulate 
activity of IGF1R directly or indirectly. Our data indicate that UBQLN1 expression is one 
such candidate. Future studies investigating role of UBQLN1 in IGF pathway mediated 
tumorigenesis, metastasis, response and resistance to therapy are warranted. Refer to 




































Figure 36: Model of regulation of IGF1R by UBQLN1: When 
UBQLN1 is present, it interacts with IGF1R from the time of its 
synthesis and assembly in the ER to processing in the Golgi to 
transport to the cell surface and continues to be recruited to the 
receptor upon ligand stimulation and internalization. Presence of 
UBQLN1 (A) allows normal recycling and turnover of the receptor. 
Absence of UBQLN1 (B) prevents normal recycling of the receptor, 
causes its accumulation and leads to eventual degradation by 






Overall Goals and Specific Aims  
 The Ubiquilin family proteins are implicated in a variety of cellular processes like 
autophagy, ERAD, receptor trafficking, proteasomal degradation, substrate stabilization 
and diseases like neurodegeneration and cancer. The overall goal of this dissertation 
was to identify a mechanism of action for UBQLN1.  To do so, we developed the 
following aims:  
Specific Aims 
1) To investigate biochemical functions of UBQLN1  
a) Identify domains of UBQLN1 responsible for interaction with multiple substrates 
b) Determine role of UBQLN1 on substrate stability 
2) To investigate role of UBQLN1 in regulation of receptor tyrosine kinases  
a) Determine role of UBQLN1 in trafficking and turnover of IGF1R 
b) Determine biological consequences of UBQLN1 loss and dysregulation of IGF 
pathway in lung adenocarcinoma cells.  




Major Findings of this Dissertation 
 We demonstrated that Ubiquilin1 regulates transmembrane proteins like BClb, an 
anti-apoptotic mitochondrial membrane protein, insulin-like growth factor 1 receptor 
(IGF1R), a cell surface receptor tyrosine kinase, Extended Synaptotagmin 2 (ESYT2), a 
calcium sensing protein localized at ER-plasma membrane contact sites. The STI domains 
of UBQLN1 are essential for interaction with these substrates while the UBA domain is 
required to protect them from degradation.  
1. BCLb 
 Using BCLb as a model substrate, we characterized UBQLN1-substrate 
interaction. We identified the first two STI domains of UBQLN1 as critical for binding to 
BCLb. Interaction of UBQLN1 with BCLb is independent of ubiquitination of BCLb, but 
interaction with ubiquitin via UBA domain is required for stabilization of BCLb. Similarly, 
we showed that UBQLN1 interacts with IGF1R and ESYT2 through the STI domains and 
stabilizes these proteins through its UBA domain. Interactions that are not dependent on 
STI domains, for example, UBL mediated interaction with PSMD4 and BAG6, do not 
appear to be stabilized by UBQLN1. We conclude that fate of substrates that UBQLN1 
associates with, is interaction domain specific. 
2. ESYT2 
 There are three Extended Synaptotagmin proteins (ESYT1/2/3).  ESYTs have an 
N-terminal ER-membrane binding domain, a mitochondrial-lipid-binding protein domain 
(SMP), and multiple calcium sensing C2 domains (Min, Chang, & Südhof, 2007). Proteins 
like ESYTs connect the vast ER network to different compartments in the cell like plasma 
membrane and mitochondria and facilitate exchange of molecules and ions and regulate 
cell signaling between these compartments. ESYT2/3 are not integral membrane proteins 
like ESYT1, but are inserted into the ER membrane through its N-terminal transmembrane 




shown that ESYT2 interacts with activated Fibroblast Growth Factor Receptor (FGFR) 
(Tremblay et al., 2015). Subsequently, ESYT2 interacts with early endosome marker 
EEA1 during the internalization phase of FGFR upon activation with FGF. Additionally, 
ESYT2 interacts with AP2, another protein involved in clathrin-mediated endocytosis 
(Jean et al., 2010). Our data demonstrate that UBQLN1 strongly interacts with ESYT1 and 
ESYT2 but not with ESYT3 (Immunoprecipitation/Mass Spectrometry). We confirmed that 
STI domains of UBQLN1 are critical in binding to ESYT2 (Immunoprecipitation/Western 
Blot) and the UBA domain protects it from MG132 induced degradation (Kurlawala et al., 
2017). 
3. Receptor Tyrosine Kinases (IGF1R, IGF2R, INSR, EGFR) 
 Our IP/MS and IP/WB data indicate that Ubiquilin1 interacts with IGF1R, IGF2R 
and INSR. Like with BCLb, the STI-1 and STI-2 domains are responsible for interaction 
with IGF1R and the UBA domain is critical in protecting it from MG132 (proteasomal 
inhibitor) induced degradation.  
 Next, we chose to study effects of loss of UBQLN1 on IGF1R in a lung 
adenocarcinoma cell line as IGF receptors are overexpressed in lung cancers. We 
demonstrate here that UBQLN1 regulates expression and activity of IGF1R. Following 
loss of UBQLN1 in lung adenocarcinoma cells, there is accelerated loss of IGF1R, partially 
rescued by blocking the proteasome. Despite decreased levels of total receptors, the ratio 
of active:total receptors is higher in cells that lack UBQLN1. UBQLN1 also regulates INSR 
and IGF2R post-stimulation with ligand. We conclude that UBQLN1 is essential for normal 
regulation of IGF1R. UBQLN1 deficient cells demonstrate increased survival when serum 
starved and stimulation of IGF pathway in these cells increased their migratory potential 
by 3-fold.  
 Additionally, we found that UBQLN1 and UBQLN2 interact with EGFR. UBQLN1 




4. Substrate Stabilization Model for Ubiquilin1  
 We demonstrated that STI and UBA mediated interactions of Ubiquilin1 result in 
proteostasis of three transmembrane proteins such that primary association of UBQLN1 
with substrate occurs through the STI domains and a secondary association 
through its UBA domain leads to stabilization of the substrate. Additionally, we 
showed that the UBA domain of Ubiquilin1 binds non-preferentially to different ubiquitin 
linkages, Ubiquilin1 dimerizes through its STI-4 domains and Ubiquilin1 continues to 
interact with its substrates in its monomeric and dimerized forms (Kurlawala et al., 2017).  
 
Strengths of this Dissertation 
Ubiquilin1 was discovered in 1999, followed by its other family members. UBQLN 
proteins are evolutionary conserved and have distinct tissue distribution therefore these 
proteins seem to be important from an evolutionary standpoint. We developed constructs 
of UBQLN1 to study functions of individual domains of the protein and their general role 
upon interaction with substrate. We tried to identify patterns in UBQLN1-substrate 
interaction based on literature and our data and classified substrates of UBQLN1 into 2 
categories – stabilizers and degraders, thus helping us understand its mechanism of 
action. We demonstrated that Ubiquilin1 may be a key regulator of transmembrane 
proteins like BCLb, IGF1R, INSR, ESYT2 and EGFR and potentially influence their 
activity.  
 
Limitations of this Dissertation 
We did not test whether interaction of UBQLN1 with its substrates was a direct or 
indirect interaction. Irrespective of the type of interaction, UBQLN1 continues to regulate 
BCLb, ESYT2, and receptor tyrosine kinases we tested. Next, the domain deletion 




binding with substrates. Although, theoretically changes in folding can affect binding, we 
continued to detect interactions for UBQLN1 with DSTI domain, DUBL and DUBA domains 
for the proteins we tested. Thirdly, we did not test for compensation by other UBQLN family 
members in cells that have loss of UBQLN1 function, which may be responsible for lack 
of phenotype in some cell types. Regulation of receptor tyrosine kinases were tested in a 
2D in vitro model and cellular confluency is known to influence expression and activity of 
cell surface receptors. Therefore, regulation of receptor tyrosine kinases by UBQLN1 
should be tested in a more relevant 3D model and in vivo.  
 
Future directions 
So far, we have only scratched the surface of understanding the mechanics of 
interaction between UBQLN1 and its substrates. Detailed experiments characterizing their 
regulation are warranted. For example, are cancers with loss of UBQLN1 and over-
expression of IGF1R and EGFR more sensitive to IGFR and EGFR activity inhibition? 
ESYT proteins are calcium sensing proteins present at ER-plasma membrane contact 
sites and participate in connecting cellular compartments (Sclip, Bacaj, Giam, & Sudhof, 
2016) UBQLN1 interacts with several transmembrane proteins which directly or indirectly 
interact with cytoskeletal proteins like Vimentin (A. L. Wu et al., 1999). Does UBQLN1 act 
as a scaffold to hold protein complexes together and may also play a role in preserving 
normal cellular morphology and signaling networks? Identifying interactions of UBQLN1 
with components of the membrane and cytoskeleton using co-immunoprecipitation 
analysis, crosslinking protein interaction assays for detection of transient interactions, 
visualization of contact sites and tracking changes in live cells via immunofluorescence 
and electron microscopy will be valuable. Previously, Ubiquilin2 has been shown to 
negatively regulate clathrin-mediated endocytosis of G Protein-Coupled Receptors 




(ubiquitin interacting motif) of EPS15, Hrs, Hbp (Regan-Klapisz et al., 2005). These 
proteins form a multi-complex and assist in sorting of ubiquitinated cargo (endocytosed 
EGF receptor) into multi-vesicular bodies (Gucwa & Brown, 2014). Whether Ubiquilin1 
participates in a similar complex for regulation of IGF1R and EGFR is not known. As 
IGF1R is involved in processes of normal growth, development, metabolism and even 
cancer progression, understanding its regulation by Ubiquilin1 can be of tremendous value 
to many disciplines. 
 
Conclusions 
We identified 5 new transmembrane proteins as substrates of UBQLN1: ESYT2, 
IGF1R, IGF2R, INSR and EGFR. We proposed a new substrate stabilization model such 
that these proteins primarily interact with UBQLN1 through its STI domains and are 
stabilized by a secondary association via the UBA domain (tested only for BCLb, ESYT2, 
IGF1R). UBL-mediated interactions with BAG6 and PSMD4 do not result in their 
stabilization.  
Using these data, we determined that UBQLN1 is essential in regulation of IGF1R in 
lung adenocarcinoma cells. Loss of UBQLN1 leads to accelerated loss of IGF1R. Loss of 
UBQLN1 leads to increased activation of the IGF pathway leading to increased survival 
and migration of these cells. Additionally, we found that UBQLN1 also interacts with Insulin 
receptor, IGF2R and EGFR.  
Overall, we conclude that Ubiquilin1 performs a variety of functions in cells and fate 
of substrates it binds to is interaction-domain specific. Individual domains may determine 
Ubiquilin1’s underlying mechanism of action and elucidate its role in neurodegenerative 
disorders as well as in cancers. Ubiquilin1 may play an important role in endocytosis and 
trafficking of proteins. Whether this role is via its UBA domain associating with ubiquitin 
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